WO2021136263A1 - 一种经修饰的免疫效应细胞及其制备方法 - Google Patents
一种经修饰的免疫效应细胞及其制备方法 Download PDFInfo
- Publication number
- WO2021136263A1 WO2021136263A1 PCT/CN2020/140799 CN2020140799W WO2021136263A1 WO 2021136263 A1 WO2021136263 A1 WO 2021136263A1 CN 2020140799 W CN2020140799 W CN 2020140799W WO 2021136263 A1 WO2021136263 A1 WO 2021136263A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- immune effector
- hla
- cells
- expression
- Prior art date
Links
- 239000012642 immune effector Substances 0.000 title claims abstract description 129
- 229940121354 immunomodulator Drugs 0.000 title claims abstract description 129
- 238000002360 preparation method Methods 0.000 title claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 210
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 claims abstract description 192
- 230000014509 gene expression Effects 0.000 claims abstract description 156
- 230000000694 effects Effects 0.000 claims abstract description 121
- 101150118346 HLA-A gene Proteins 0.000 claims abstract description 107
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims abstract description 90
- 230000001105 regulatory effect Effects 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 58
- 101150076800 B2M gene Proteins 0.000 claims abstract description 48
- 210000004027 cell Anatomy 0.000 claims description 355
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 109
- 102000004169 proteins and genes Human genes 0.000 claims description 103
- 206010028980 Neoplasm Diseases 0.000 claims description 88
- 239000002773 nucleotide Substances 0.000 claims description 74
- 125000003729 nucleotide group Chemical group 0.000 claims description 73
- 230000004048 modification Effects 0.000 claims description 70
- 238000012986 modification Methods 0.000 claims description 70
- 239000000427 antigen Substances 0.000 claims description 69
- 108091007433 antigens Proteins 0.000 claims description 69
- 102000036639 antigens Human genes 0.000 claims description 69
- 108091033409 CRISPR Proteins 0.000 claims description 65
- 230000027455 binding Effects 0.000 claims description 54
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 50
- 230000008685 targeting Effects 0.000 claims description 46
- 150000007523 nucleic acids Chemical class 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 32
- 108020005544 Antisense RNA Proteins 0.000 claims description 29
- -1 CD3e Proteins 0.000 claims description 29
- 239000003184 complementary RNA Substances 0.000 claims description 29
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 239000004055 small Interfering RNA Substances 0.000 claims description 22
- 108020004459 Small interfering RNA Proteins 0.000 claims description 21
- 230000000139 costimulatory effect Effects 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 20
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 19
- 238000010354 CRISPR gene editing Methods 0.000 claims description 17
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 16
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 230000000735 allogeneic effect Effects 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 13
- 230000030279 gene silencing Effects 0.000 claims description 13
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 12
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 12
- 230000002222 downregulating effect Effects 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 238000012226 gene silencing method Methods 0.000 claims description 11
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 10
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 7
- 206010064571 Gene mutation Diseases 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 6
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 239000002924 silencing RNA Substances 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 3
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 claims description 2
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 description 86
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 83
- 108010075704 HLA-A Antigens Proteins 0.000 description 83
- 108020005004 Guide RNA Proteins 0.000 description 55
- 238000003209 gene knockout Methods 0.000 description 51
- 108700028369 Alleles Proteins 0.000 description 47
- 108700002010 MHC class II transactivator Proteins 0.000 description 45
- 102100026371 MHC class II transactivator Human genes 0.000 description 43
- 108020004999 messenger RNA Proteins 0.000 description 37
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 33
- 108091028113 Trans-activating crRNA Proteins 0.000 description 32
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 230000008859 change Effects 0.000 description 28
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 27
- 238000010453 CRISPR/Cas method Methods 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 25
- 229920002477 rna polymer Polymers 0.000 description 24
- 101710163270 Nuclease Proteins 0.000 description 22
- 230000006870 function Effects 0.000 description 22
- 230000000295 complement effect Effects 0.000 description 21
- 238000003197 gene knockdown Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 238000001514 detection method Methods 0.000 description 17
- 201000001441 melanoma Diseases 0.000 description 17
- 238000007480 sanger sequencing Methods 0.000 description 16
- 102000053602 DNA Human genes 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 15
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 15
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 13
- 102100029198 SLAM family member 7 Human genes 0.000 description 13
- 108091008874 T cell receptors Proteins 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 210000000822 natural killer cell Anatomy 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 12
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 101710145634 Antigen 1 Proteins 0.000 description 10
- 102000001301 EGF receptor Human genes 0.000 description 10
- 108060006698 EGF receptor Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 9
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 9
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 9
- 102100038083 Endosialin Human genes 0.000 description 9
- 102000010956 Glypican Human genes 0.000 description 9
- 108050001154 Glypican Proteins 0.000 description 9
- 108050007237 Glypican-3 Proteins 0.000 description 9
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 9
- 108010081734 Ribonucleoproteins Proteins 0.000 description 9
- 102000004389 Ribonucleoproteins Human genes 0.000 description 9
- 206010039491 Sarcoma Diseases 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 210000004180 plasmocyte Anatomy 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 102210047469 A*02:01 Human genes 0.000 description 8
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 description 7
- 102210048101 A*01:01 Human genes 0.000 description 7
- 102210042961 A*03:01 Human genes 0.000 description 7
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 7
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 7
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 7
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 7
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 7
- 108010036972 HLA-A11 Antigen Proteins 0.000 description 7
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 7
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 7
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 7
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 7
- 102100034256 Mucin-1 Human genes 0.000 description 7
- 108010008707 Mucin-1 Proteins 0.000 description 7
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 7
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 7
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 7
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 7
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 108010072257 fibroblast activation protein alpha Proteins 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- LTHJXDSHSVNJKG-UHFFFAOYSA-N 2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOCCOC(=O)C(C)=C LTHJXDSHSVNJKG-UHFFFAOYSA-N 0.000 description 6
- 102210048100 A*31:01 Human genes 0.000 description 6
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 6
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 6
- 108700012439 CA9 Proteins 0.000 description 6
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 6
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 102000012466 Cytochrome P450 1B1 Human genes 0.000 description 6
- 108050002014 Cytochrome P450 1B1 Proteins 0.000 description 6
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 6
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 6
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 6
- 102100036939 G-protein coupled receptor 20 Human genes 0.000 description 6
- 101710108873 G-protein coupled receptor 20 Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 101000884275 Homo sapiens Endosialin Proteins 0.000 description 6
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 description 6
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 6
- 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 description 6
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 6
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 6
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 6
- 241000701806 Human papillomavirus Species 0.000 description 6
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 6
- 102100022339 Integrin alpha-L Human genes 0.000 description 6
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 description 6
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 6
- 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 description 6
- 101710196509 Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 description 6
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 6
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 6
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 6
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 6
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 description 6
- 101710187841 Olfactory receptor 51E2 Proteins 0.000 description 6
- 108700020796 Oncogene Proteins 0.000 description 6
- 102100032364 Pannexin-3 Human genes 0.000 description 6
- 101710165197 Pannexin-3 Proteins 0.000 description 6
- 102100026181 Placenta-specific protein 1 Human genes 0.000 description 6
- 108050005093 Placenta-specific protein 1 Proteins 0.000 description 6
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 6
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 6
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 6
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 6
- 102100038098 Protein-glutamine gamma-glutamyltransferase 5 Human genes 0.000 description 6
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 6
- 101800001271 Surface protein Proteins 0.000 description 6
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 6
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 6
- 102000013532 Uroplakin II Human genes 0.000 description 6
- 108010065940 Uroplakin II Proteins 0.000 description 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 6
- 102100039490 X antigen family member 1 Human genes 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 108010051081 dopachrome isomerase Proteins 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 6
- 208000014829 head and neck neoplasm Diseases 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 6
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- 210000001550 testis Anatomy 0.000 description 6
- 108010058721 transglutaminase 5 Proteins 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 102100029599 Advanced glycosylation end product-specific receptor Human genes 0.000 description 5
- 101710168586 Advanced glycosylation end product-specific receptor Proteins 0.000 description 5
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 5
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 5
- 108010051118 Bone Marrow Stromal Antigen 2 Proteins 0.000 description 5
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 description 5
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 5
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 description 5
- 101000890604 Homo sapiens A-kinase anchor protein 4 Proteins 0.000 description 5
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 5
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 description 5
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 5
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 5
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 5
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 5
- 101710107067 Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 5
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 5
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 5
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 5
- 102100029337 Thyrotropin receptor Human genes 0.000 description 5
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 5
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012033 transcriptional gene silencing Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 102100038078 CD276 antigen Human genes 0.000 description 4
- 108060001253 CD99 Proteins 0.000 description 4
- 102000024905 CD99 Human genes 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 102100036466 Delta-like protein 3 Human genes 0.000 description 4
- 208000017815 Dendritic cell tumor Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101150029707 ERBB2 gene Proteins 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 4
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 4
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 4
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 4
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 4
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 4
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 4
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 description 4
- 102100039904 Integrin alpha-D Human genes 0.000 description 4
- 102100022341 Integrin alpha-E Human genes 0.000 description 4
- 102100022338 Integrin alpha-M Human genes 0.000 description 4
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- 102100025304 Integrin beta-1 Human genes 0.000 description 4
- 102000003812 Interleukin-15 Human genes 0.000 description 4
- 108090000172 Interleukin-15 Proteins 0.000 description 4
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100023123 Mucin-16 Human genes 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 102100027610 Rho-related GTP-binding protein RhoC Human genes 0.000 description 4
- 108010057163 Ribonuclease III Proteins 0.000 description 4
- 102000003661 Ribonuclease III Human genes 0.000 description 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100035721 Syndecan-1 Human genes 0.000 description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 4
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 4
- 238000011467 adoptive cell therapy Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000019113 chromatin silencing Effects 0.000 description 4
- 229940127276 delta-like ligand 3 Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000003444 follicular lymphoma Diseases 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 206010038038 rectal cancer Diseases 0.000 description 4
- 201000001275 rectum cancer Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108010073531 rhoC GTP-Binding Protein Proteins 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 3
- 102210047117 A*02:05 Human genes 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 102000017918 ADRB3 Human genes 0.000 description 3
- 108060003355 ADRB3 Proteins 0.000 description 3
- 241000714175 Abelson murine leukemia virus Species 0.000 description 3
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 description 3
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 description 3
- 102100032187 Androgen receptor Human genes 0.000 description 3
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 description 3
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 description 3
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- 206010006143 Brain stem glioma Diseases 0.000 description 3
- 102100023458 C-type lectin-like domain family 1 Human genes 0.000 description 3
- 102100024263 CD160 antigen Human genes 0.000 description 3
- 102000007645 CD24 Antigen Human genes 0.000 description 3
- 108010071965 CD24 Antigen Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 108010058905 CD44v6 antigen Proteins 0.000 description 3
- 102100037904 CD9 antigen Human genes 0.000 description 3
- 101710120600 Cancer/testis antigen 1 Proteins 0.000 description 3
- 101710120595 Cancer/testis antigen 2 Proteins 0.000 description 3
- 108010051152 Carboxylesterase Proteins 0.000 description 3
- 102000013392 Carboxylesterase Human genes 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 101710181340 Chaperone protein DnaK2 Proteins 0.000 description 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 3
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 108010060385 Cyclin B1 Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100031334 Elongation factor 2 Human genes 0.000 description 3
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 101710144543 Endosialin Proteins 0.000 description 3
- 102000050554 Eph Family Receptors Human genes 0.000 description 3
- 108091008815 Eph receptors Proteins 0.000 description 3
- 102100023721 Ephrin-B2 Human genes 0.000 description 3
- 108010044090 Ephrin-B2 Proteins 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 201000001342 Fallopian tube cancer Diseases 0.000 description 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 3
- 102000010451 Folate receptor alpha Human genes 0.000 description 3
- 108050001931 Folate receptor alpha Proteins 0.000 description 3
- 102000010449 Folate receptor beta Human genes 0.000 description 3
- 108050001930 Folate receptor beta Proteins 0.000 description 3
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 3
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 3
- 108010084795 Fusion Oncogene Proteins Proteins 0.000 description 3
- 102000005668 Fusion Oncogene Proteins Human genes 0.000 description 3
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 3
- 102000044445 Galectin-8 Human genes 0.000 description 3
- 102100039554 Galectin-8 Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 3
- 101710178419 Heat shock protein 70 2 Proteins 0.000 description 3
- 241000709721 Hepatovirus A Species 0.000 description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 description 3
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 description 3
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 description 3
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 3
- 101000906643 Homo sapiens C-type lectin-like domain family 1 Proteins 0.000 description 3
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 3
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 3
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 3
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 3
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 description 3
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 3
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 3
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 3
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 3
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 3
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000004553 Interleukin-11 Receptors Human genes 0.000 description 3
- 108010017521 Interleukin-11 Receptors Proteins 0.000 description 3
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 3
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 3
- 102100034872 Kallikrein-4 Human genes 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 101710094902 Legumin Proteins 0.000 description 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 3
- 108010015372 Low Density Lipoprotein Receptor-Related Protein-2 Proteins 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 3
- 108010010995 MART-1 Antigen Proteins 0.000 description 3
- 102000016200 MART-1 Antigen Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 3
- 102000008840 Melanoma-associated antigen 1 Human genes 0.000 description 3
- 108050000731 Melanoma-associated antigen 1 Proteins 0.000 description 3
- 102000003735 Mesothelin Human genes 0.000 description 3
- 108090000015 Mesothelin Proteins 0.000 description 3
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 3
- 208000002471 Penile Neoplasms Diseases 0.000 description 3
- 206010034299 Penile cancer Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 3
- 201000005746 Pituitary adenoma Diseases 0.000 description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 description 3
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 3
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 3
- 102100037891 Plexin domain-containing protein 1 Human genes 0.000 description 3
- 108050009432 Plexin domain-containing protein 1 Proteins 0.000 description 3
- 102100040120 Prominin-1 Human genes 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 102100029197 SLAM family member 6 Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 3
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 3
- 102100022441 Sperm surface protein Sp17 Human genes 0.000 description 3
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 description 3
- 206010057644 Testis cancer Diseases 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 101710081844 Transmembrane protease serine 2 Proteins 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 3
- 206010046392 Ureteric cancer Diseases 0.000 description 3
- 206010046431 Urethral cancer Diseases 0.000 description 3
- 206010046458 Urethral neoplasms Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 101710101493 Viral myc transforming protein Proteins 0.000 description 3
- 206010047741 Vulval cancer Diseases 0.000 description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 201000005188 adrenal gland cancer Diseases 0.000 description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 3
- 108010080146 androgen receptors Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 3
- 210000000750 endocrine system Anatomy 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 231100000221 frame shift mutation induction Toxicity 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 150000002402 hexoses Chemical group 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 108010024383 kallikrein 4 Proteins 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 3
- 208000026037 malignant tumor of neck Diseases 0.000 description 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 230000037434 nonsense mutation Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 101710135378 pH 6 antigen Proteins 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 108010079891 prostein Proteins 0.000 description 3
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 125000005630 sialyl group Chemical group 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 208000037959 spinal tumor Diseases 0.000 description 3
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 108010042703 synovial sarcoma X breakpoint proteins Proteins 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 201000011294 ureter cancer Diseases 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- 206010046885 vaginal cancer Diseases 0.000 description 3
- 208000013139 vaginal neoplasm Diseases 0.000 description 3
- 201000005102 vulva cancer Diseases 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 102100022987 Angiogenin Human genes 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 108010017009 CD11b Antigen Proteins 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 102100038449 Claudin-6 Human genes 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102210024048 HLA-A*01:01 Human genes 0.000 description 2
- 102210024049 HLA-A*03:01 Human genes 0.000 description 2
- 108010021727 HLA-A*24:02 antigen Proteins 0.000 description 2
- 102220404670 HLA-A*33:01 Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 2
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100025323 Integrin alpha-1 Human genes 0.000 description 2
- 102100033016 Integrin beta-7 Human genes 0.000 description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010051809 Myelocytosis Diseases 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- WSDRAZIPGVLSNP-UHFFFAOYSA-N O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O Chemical compound O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O WSDRAZIPGVLSNP-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102000005435 Receptor Tyrosine Kinase-like Orphan Receptors Human genes 0.000 description 2
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 108010002321 Tight Junction Proteins Proteins 0.000 description 2
- 102000000591 Tight Junction Proteins Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 102000005421 acetyltransferase Human genes 0.000 description 2
- 108020002494 acetyltransferase Proteins 0.000 description 2
- 239000007825 activation reagent Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000011398 antitumor immunotherapy Methods 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 102000027596 immune receptors Human genes 0.000 description 2
- 108091008915 immune receptors Proteins 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 102000021127 protein binding proteins Human genes 0.000 description 2
- 108091011138 protein binding proteins Proteins 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 206010042863 synovial sarcoma Diseases 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 241001135192 Acetohalobium arabaticum Species 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000640374 Alicyclobacillus acidocaldarius Species 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 241000620196 Arthrospira maxima Species 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 241000906059 Bacillus pseudomycoides Species 0.000 description 1
- 241000823281 Burkholderiales bacterium Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000589986 Campylobacter lari Species 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000907165 Coleofasciculus chthonoplastes Species 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 description 1
- 102000047351 Exportin-5 Human genes 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 241000605896 Fibrobacter succinogenes Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000589599 Francisella tularensis subsp. novicida Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 102000018638 GTP binding domains Human genes 0.000 description 1
- 108050007795 GTP binding domains Proteins 0.000 description 1
- 241001416183 Ginglymostomatidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102210042925 HLA-A*02:01 Human genes 0.000 description 1
- 102220404671 HLA-A*11:01 Human genes 0.000 description 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 101000847058 Homo sapiens Exportin-5 Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 241001112693 Lachnospiraceae Species 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 241001134698 Lyngbya Species 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000501784 Marinobacter sp. Species 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 241000192701 Microcystis Species 0.000 description 1
- 241000190905 Microscilla Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 241000919925 Nitrosococcus halophilus Species 0.000 description 1
- 241000203619 Nocardiopsis dassonvillei Species 0.000 description 1
- 241001223105 Nodularia spumigena Species 0.000 description 1
- 241000192673 Nostoc sp. Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000192520 Oscillatoria sp. Species 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
- 101710149060 Paired box protein Pax-3 Proteins 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- 101710149067 Paired box protein Pax-5 Proteins 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- 241001599925 Polaromonas naphthalenivorans Species 0.000 description 1
- 241001472610 Polaromonas sp. Species 0.000 description 1
- 108010068086 Polyubiquitin Proteins 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 241001135241 Porphyromonas macacae Species 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 1
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000190984 Rhodospirillum rubrum Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241001518258 Streptomyces pristinaespiralis Species 0.000 description 1
- 241000187191 Streptomyces viridochromogenes Species 0.000 description 1
- 241000203587 Streptosporangium roseum Species 0.000 description 1
- 241000192560 Synechococcus sp. Species 0.000 description 1
- 101710191487 T cell receptor alpha chain constant Proteins 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 241000206213 Thermosipho africanus Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 241000078013 Trichormus variabilis Species 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 1
- 241000605939 Wolinella succinogenes Species 0.000 description 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- DILVWDXOASDRPN-MROZADKFSA-N [(2r,3r,4r)-3,4,5-trihydroxy-1-oxopentan-2-yl] dihydrogen phosphate Chemical group OC[C@@H](O)[C@@H](O)[C@H](C=O)OP(O)(O)=O DILVWDXOASDRPN-MROZADKFSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000011129 allogeneic cell therapy Methods 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940011019 arthrospira platensis Drugs 0.000 description 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 description 1
- 210000002769 b effector cell Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- GRPSNTXTTSBKGW-BVGHQBMWSA-J magnesium;potassium;sodium;(3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;triacetate;chloride Chemical compound [Na+].[Mg+2].[Cl-].[K+].CC([O-])=O.CC([O-])=O.CC([O-])=O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O GRPSNTXTTSBKGW-BVGHQBMWSA-J 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Definitions
- This application relates to the field of biomedicine, in particular to a modified immune effector cell and a preparation method thereof.
- Anti-tumor immunotherapy can cause a long-lasting and strong response in a variety of malignant tumors, can be used to treat many different types of cancer, and shows a wide range of potential.
- Current anti-tumor immunotherapy mainly includes two types of immunotherapy: immune cell-targeted monoclonal antibody (mAb) therapy and adoptive cell therapy (ACT).
- mAb monoclonal antibody
- ACT adoptive cell therapy
- ACT refers to the reinfusion of autologous or allogeneic lymphocytes stimulated and expanded in vitro into the human body to achieve the anti-tumor effect, but this therapy is only effective in patients with consistent MHC polymorphisms.
- CAR-T is a new and effective MHC-independent adoptive cell therapy.
- CAR also known as chimeric antigen receptor
- CAR is an artificial receptor that mimics the function of TCR. It can specifically recognize antigens on the surface of tumor cells to target killing. Dead tumor cells.
- the timely and successful production and infusion of autologous CAR T cells is the biggest obstacle to the implementation of effective CAR T cell therapy.
- the patient was treated with chemotherapy before, and chemotherapy drugs will cause the patient's T cells to expand in vitro or reduce their function, resulting in failure to produce A sufficient quantity of CAR-T cell products, or poor quality.
- autologous CAR-T is mostly used in ALL or CLL patients, and its application in solid tumor patients faces great challenges. For example, the heterogeneity of tumor antigens limits the application of autologous CAR-T.
- the present application provides a modified immune effector cell, wherein the expression and/or activity of the TRAC gene and the HLA-A gene are down-regulated compared with the expression and/or activity of the corresponding gene in the corresponding cell without the modification ,
- the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or activity of the CIITA gene is not down-regulated.
- the modification causes the expression and/or activity of two genes to be down-regulated, wherein the two genes consist of the TRAC gene and the HLA-A gene.
- the expression and/or activity of the TRAC gene and HLA-A gene are down-regulated, the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or activity of the CIITA gene is not down-regulated compared with the corresponding wild-type cell. /Or the activity is not down-regulated.
- the expression and/or activity of two genes are down-regulated compared to corresponding wild-type cells, wherein the two genes consist of the TRAC gene and the HLA-A gene.
- the immune effector cells include T cells.
- the down-regulation of the expression level and/or activity of the gene includes down-regulating the expression and/or activity of the nucleic acid molecule encoding the gene; and/or down-regulating the expression and/or expression of the protein product encoded by the gene / Or the activity is down-regulated.
- the modification includes: gene mutation and/or gene silencing.
- the modification includes administering one or more substances selected from the group consisting of antisense RNA, siRNA, shRNA, and CRISPR/Cas9 system to the immune effector cell.
- the modification includes administering the CRISPR/Cas9 system to the immune effector cells.
- the alleles of the HLA-A gene are selected from the following group: A*02, A*11, A*24, A*30, A*33, A*03, A*01 and A*26.
- the expression level and/or activity of at most 2 alleles in the HLA-A gene are down-regulated.
- the expression level and/or activity of one allele in the HLA-A gene is down-regulated.
- the modification includes administering to the immune effector cell an sgRNA targeting the exon portion of the HLA-A gene.
- the sgRNA targeted to the exon part of the HLA-A gene comprises the nucleotide sequence shown in any one of SEQ ID Nos. 16-54 and 91-92.
- the modification further comprises administering sgRNA targeting the exon part of the TRAC gene to the immune effector cell.
- the sgRNA targeted to the exon part of the TRAC gene comprises the nucleotide sequence shown in any one of SEQ ID No. 1-15.
- the antisense RNA comprises the nucleotide sequence shown in any one of SEQ ID No. 93-96.
- the modification further comprises administering a Cas protein to the cell.
- the Cas protein includes Cas9 protein.
- the immune effector cell comprises a nucleic acid encoding a chimeric antigen receptor (CAR), which includes an antigen binding domain, a hinge region, a transmembrane domain, a costimulatory structure, and a primary signaling structure area.
- CAR chimeric antigen receptor
- the antigen binding domain specifically binds to tumor antigens.
- the tumor antigen is selected from the following group: CD19, CD133, CD123, CD22, CD30, CD171, CA125, C-met, L1CAM, EC, DLL3, CD99, CS1, 5T4, CD138, CS- 1 (also known as CD2 subclass 1, CRACC, SLAMF7, CD319 or 19A24), C-type lectin-like molecule-1 (CLL-1 or CLECL1), CD33, epidermal growth factor receptor variant III (EGFRvIII), nerve Ganglioside G2 (GD2), Ganglioside GD3, TNF receptor family member B cell maturation antigen (BCMA), Tn antigen (such as Tn'Ag, GalNAc ⁇ -Ser/Thr), prostate specific membrane antigen (PSMA); Receptor tyrosine kinase-like orphan receptor 1 (ROR1), Fms-like tyrosine kinase 3 (FLT3); tumor-associated glycoprotein 72 (TAG72), CD38,
- the antigen-binding domain is selected from the group consisting of monoclonal antibodies, polyclonal antibodies, human antibodies, humanized antibodies, single domain antibodies, and antigen-binding fragments thereof.
- the antigen binding domain targets solid tumors.
- the solid tumor is selected from the following group: lung cancer, breast cancer, colon cancer, renal cell carcinoma, liver cancer, non-small cell lung cancer, small bowel cancer, esophageal cancer, bone cancer, pancreatic cancer, skin cancer, Head or neck cancer, skin or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin's lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, childhood solid tumor, bladder cancer, kidney or ureter cancer, renal pelvis cancer , Central Nervous System (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal tumors, brainstem glioma, pituitary adenoma,
- CNS
- the antigen binding domain targets non-solid tumors.
- the non-solid tumor is selected from the group consisting of chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T cell Acute lymphoid leukemia (T-ALL), chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), B-cell young lymphocytic leukemia, blastic plasmacytoid dendritic cell tumor, Burkitt lymphoma, diffuse Large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small or large cell follicular lymphoma, malignant lymphoproliferative disease, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma , Myelodysplastic and myelodysplastic syndrome, Hodgkin’s lymphoma, plasmablastic lymphoma, plasmacytoi
- the transmembrane domain comprises a protein derived from a protein selected from the group consisting of CD28, CD3e, CD27, CD3 ⁇ , CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, CD19, IL2R ⁇ , IL2R ⁇ , IL7R ⁇ , ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2.
- the costimulatory domain comprises a costimulatory domain selected from the following proteins: CD137, CD28, CD27, OX40, CD30, CD40, PD-1, ICOS, LFA-1, CD2, CD7 , CD160 (BY55), LIGHT, NKG2C, B7-H3, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD19, CD4, CD8 ⁇ , CD8 ⁇ , IL2R ⁇ , IL2R ⁇ , IL7R ⁇ , ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2 CD18, ITGB7, TNFR2, TRANCE/RANKL, DNAM1
- the primary intracellular signaling domain comprises a functional signaling domain selected from the following proteins: CD3 ⁇ , FcR ⁇ (FCER1G), Fc ⁇ RIIa, FcR ⁇ (Fc ⁇ R1b), CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD79a, CD79b, DAP10 and/or DAP12.
- a functional signaling domain selected from the following proteins: CD3 ⁇ , FcR ⁇ (FCER1G), Fc ⁇ RIIa, FcR ⁇ (Fc ⁇ R1b), CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD79a, CD79b, DAP10 and/or DAP12.
- the hinge region connects the antigen binding domain and the transmembrane domain, and the hinge region comprises a hinge region derived from a protein selected from the group consisting of: human Ig (immunoglobulin) hinge Region, GS linker, KIR2DS2 hinge region or CD8a hinge region.
- This application also provides a method for preparing the modified immune effector cell described in this application, which comprises the following steps: down-regulating the expression and/or activity of the corresponding gene in the corresponding cell without the modification.
- Expression and/or activity of TRAC gene and HLA-A gene in immune effector cells Does not down-regulate the expression and/or activity of the B2M gene, and does not down-regulate the expression and/or activity of the CIITA gene.
- the modification causes the expression and/or activity of two genes to be down-regulated, wherein the two genes consist of the TRAC gene and the HLA-A gene.
- the expression and/or activity of the TRAC gene and HLA-A gene are down-regulated, the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or activity of the CIITA gene is not down-regulated compared with the corresponding wild-type cell. /Or the activity is not down-regulated.
- the expression and/or activity of two genes are down-regulated compared to corresponding wild-type cells, wherein the two genes consist of the TRAC gene and the HLA-A gene.
- the down-regulating the expression level and/or activity of the gene includes down-regulating the expression and/or activity of the nucleic acid molecule encoding the gene; and/or down-regulating the expression and/or the protein product encoded by the gene Or the activity is down-regulated.
- the modification includes: gene mutation and/or gene silencing.
- the modification includes administering one or more substances selected from the group consisting of antisense RNA, siRNA, shRNA, and CRISPR/Cas9 system to the immune effector cell.
- the modification includes administering the CRISPR/Cas9 system to the immune effector cells.
- the modification includes administering to the immune effector cell an sgRNA targeting the exon portion of the HLA-A gene.
- the sgRNA targeted to the exon part of the HLA-A gene comprises the nucleotide sequence shown in any one of SEQ ID Nos. 16-54 and 91-92.
- the modification includes administering to the immune effector cell an sgRNA targeting the exon portion of the TRAC gene.
- the sgRNA targeted to the exon part of the TRAC gene comprises the nucleotide sequence shown in any one of SEQ ID No. 1-15.
- the antisense RNA comprises the nucleotide sequence shown in any one of SEQ ID No. 93-96.
- the modification further comprises administering a Cas protein to the cell.
- the Cas protein includes Cas9 protein.
- the application also provides a composition, which includes the modified immune effector cell described in the application and a pharmaceutically acceptable carrier.
- the composition includes a cell population, wherein the cell population includes the modified immune effector cells described herein.
- This application also provides the application of the modified immune effector cells described in this application in the preparation of CAR-T cells.
- the application also provides the application of the modified immune effector cells described in the application in the preparation of medicines, and the medicines are used for allogeneic therapy.
- the application also provides a method of allogeneic treatment, the method comprising administering the modified immune effector cells described in the application to a patient or a subject.
- the present application also provides the modified immune effector cells described in the present application, which are used in allogeneic therapy.
- This application also provides the application of the modified immune effector cells described in this application in the preparation of medicines for the treatment of tumors.
- the application also provides a method of treating tumors, the method comprising administering the modified immune effector cells described in the application to a patient or a subject.
- the application also provides the modified immune effector cells, which are used to treat tumors.
- the tumor includes solid tumors and non-solid tumors.
- the tumor is selected from the following group: lung cancer, breast cancer, colon cancer, renal cell cancer, liver cancer, non-small cell lung cancer, small bowel cancer, esophageal cancer, bone cancer, pancreatic cancer, skin cancer, head Or neck cancer, skin or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Huo Chikin’s disease, non-Hodgkin’s lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, urethral cancer, penile cancer, childhood solid tumor, bladder cancer, kidney or ureter cancer, renal pelvis cancer, Central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal tumors, brainstem glioma, pituitary adenoma, Kaposi
- CNS
- FIG 1 shows the results of Sanger sequencing of the TRAC gene in this application after Sg9RNA editing.
- Figure 2 shows the results of TA clone detection after Sg9RNA editing of the TRAC gene in this application.
- FIG. 3 shows the results of flow cytometric detection of the TRAC gene in this application after Sg9RNA editing.
- FIG. 4 shows the results of Sanger sequencing of the HLA-A02 gene in this application after Sg2RNA editing.
- FIG. 5 shows the results of Sanger sequencing of the HLA-A02 gene in this application after Sg5RNA editing.
- Figure 6 shows the results of Sanger sequencing of the HLA-A11 gene in this application after Sg10-3RNA editing.
- Figure 7 shows the results of Sanger sequencing of the HLA-A11 gene in this application after Sg21RNA editing.
- Figures 8A-8B show the results of simultaneous knockout of HLA-A02 and TRAC in the modified immune effector cells of the present application.
- FIGS 9A-9B show the protein levels of HLA-A02 and TRAC in the modified immune effector cells of the present application.
- Figures 10A-10D show the mRNA levels of TRAC, HLA-A, B2M and CIITA in the modified immune effector cells of the present application.
- Figures 11A-11B show the protein levels of B2M and CIITA in the modified immune effector cells of the present application.
- Figures 12A-12D show the protein levels of TRAC, HLA-A, B2M and CIITA in the modified immune effector cells of the present application.
- Figures 13A-13B show the knockout of TRAC and HLA-A mRNA levels in the modified immune effector cells of the present application.
- Figures 14A-14B show the protein levels of CD69 and CD137 in the modified immune effector cells of the present application.
- Figure 15 shows the co-culture of the modified immune effector cells of the present application and NK cells.
- Figure 16 shows the level of IFN- ⁇ expressed by the modified immune effector cells of the present application.
- Figures 17A-17D show the protein levels of TRAC, HLA-A, B2M and CIITA in the modified immune effector cells of the present application.
- Figure 18 shows the infection efficiency of the modified immune effector cells of the present application on CAR.
- Figure 19 shows the expansion factor of the modified immune effector cells of the present application.
- Figure 20 shows the killing effect of the modified immune effector cells of the present application on CD19-positive target cells.
- Figure 21 shows the dosing regimen for administering the modified immune effector cells of the present application.
- Figure 22 shows the killing effect of the modified immune effector cells of the present application on tumors in mice.
- immune effector cells generally refers to immune cells that participate in immune responses and perform effector functions.
- the exercise of effector functions may include removing foreign body antigens or promoting immune effector responses.
- Immune effector cells may include plasma cells, T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and bone marrow-derived phagocytes.
- the term "modification” generally refers to changing the state or structure of a cell and/or a change in the state or structure of a cell.
- the change is usually compared with the state or structure of the cell without the modification.
- the change may include a change in the expression level or function of the endogenous gene, for example, the expression level of the endogenous gene in the cell is down-regulated by genetic engineering means, Up-regulation or non-expression, the genetic engineering means may include homologous recombination, CRISPR/Cas9 system gene editing, etc.; the changes may also include changes in cell protein expression, structure or function, for example, through the expression level of the endogenous gene or
- the change in the expression of the corresponding protein, the change in structure or function achieved by the change in function such as the change in protein expression, the change in structure or function achieved by regulating protein translation and post-translational modification; the change may also include the introduction of foreign sources Genes, expression of foreign proteins, etc.
- T cell receptor alpha con-stant T cell receptor alpha con-stant
- T cell receptor T cell receptor
- TCR T cell receptor
- MHC major histocompatibility complex
- TCR usually consists of two different protein chains (ie heterodimers). In humans, the TCR in most T cells consists of an ⁇ chain and a ⁇ chain (encoded by TRA and TRB, respectively). This type of T cell is called ⁇ ⁇ T cell. In a small number of T cells, TCR consists of a ⁇ chain.
- ⁇ T cell this type of T cell is called ⁇ T cell.
- ⁇ T cells account for about 95% of the total number of T cells, and ⁇ T cells account for about 5% of the total number of T cells. This ratio varies during ontogeny and disease states (such as leukemia), and varies between species. different.
- Each chain that composes the TCR contains variable and constant regions.
- the gene encoding the ⁇ chain (TRA, such as the information shown in HGNC: 12027) is located on chromosome 14 and consists of multiple gene fragments, including variable Segment (V), connecting segment (J) and constant region (C).
- TRAC gene usually refers to the gene sequence encoding the constant region (C) of the alpha chain of the T cell receptor (for example, the information shown in HGNC: 12029), which is located in Chromosome 14 (14q11.2; 14: 22,547,505-22,552,131).
- C constant region
- HGNC 12029
- one of the variable segment (V) genes encoding the N segment antigen recognition domain is rearranged with one of the connecting segment (J) to produce a functional V region exon, which is transcribed and spliced with
- the constant regions (C) are connected to form the T cell receptor alpha chain coding sequence.
- HLA-A generally refers to a type of human leukocyte antigen (human leukocyte antigens) polypeptide chain, which is encoded by the HLA-A gene located on human chromosome 6p21.3 (for example, the information shown in HGNC:4931).
- HLA-A is one of the three main types of peptides that make up class I MHC molecules on the surface of human cells.
- Others include HLA-B and HLA-C.
- the heterodimer composed of the ⁇ chain encoded by the HLA-A gene and the ⁇ chain ( ⁇ 2-microglobulin) encoded by the B2M gene is the HLA-A MHC I molecule.
- the ⁇ chain encoded by the HLA-A gene may include an ⁇ 1 domain, an ⁇ 2 domain, an ⁇ 3 domain, a transmembrane region, and a cytoplasmic region, wherein the ⁇ 1 domain and the ⁇ 2 domain can be combined with the peptide fragments so that the MHC I molecules (such as HLA-A) present the peptides to cells of the immune system.
- the alpha chain of the MHC I molecule is polymorphic, and its primary structure has many changes. As of December 2013, there are 2432 known HLA-A alleles. , Encoding 1740 active proteins and 117 invalid proteins.
- HLA-A alleles may include those included in IMGT/HLA database version 3.38.0 (https://www.ebi.ac.uk/ipd/imgt/hla/) and named by the WHO HLA Factor Nomenclature Committee The sequence information of the different HLA-A alleles.
- B2M usually refers to ⁇ 2 microglobulin ( ⁇ 2-microglobulin), which is one of the components of MHC class I molecules.
- ⁇ 2 microglobulin also called ⁇ chain
- B2M is usually expressed in all nucleated cells.
- ⁇ 2 microglobulin is encoded by the B2M gene located at 15q21.1 (for example, the information shown in HGNC:914).
- CIITA generally refers to the transactivator of the major histocompatibility complex (MHCII) of class II.
- the transactivator may be a protein with an acidic transcription activation domain, 4 LRR (leucine-rich repeat sequences) and a GTP binding domain.
- the protein can be located in the cell nucleus, as a positive regulator of major histocompatibility complex (MHCII) gene transcription, and is called the "master control factor" for the expression of these genes.
- the protein can also bind to GTP and use the binding with GTP to transport itself to the nucleus, where it usually acts in a co-activator-like manner through acetyltransferase (AT) activity.
- the protein is encoded by a gene located at 16p13.13 (for example, the information shown in HGNC:7067), which can generate several transcript variants encoding different isoforms.
- wild-type cell generally refers to a naturally-occurring or naturally-derived cell.
- T cell generally refers to thymus-derived cells that participate in various cell-mediated immune responses.
- nucleic acid or “polynucleotide” or “nucleic acid molecule” generally refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers in single-stranded or double-stranded form. Unless specifically limited, the term may include nucleic acids containing analogs of natural nucleotides that have binding properties similar to the reference nucleic acid (for example, sequence information is shown) and in a manner similar to naturally occurring nucleotides. metabolism. Unless otherwise specified, the sequence of a nucleic acid may include its variants modified in a conservative manner, such as degenerate codon substitutions, alleles, orthologs, SNPs and complementary sequences, as well as the sequences explicitly indicated.
- expression generally refers to the transcription and/or translation of a specific nucleotide sequence.
- the term "gene mutation” generally refers to a change in the base pair composition or arrangement sequence of a gene in the structure. For example, point mutations caused by a single base change, or deletions, duplications, and insertions of multiple bases.
- gene silencing generally refers to preventing the expression of certain genes through regulatory mechanisms.
- TGS transcriptional gene silencing
- post-transcriptional gene silencing post-transcriptional gene silencing
- PTGS post-transcriptional gene silencing
- Gene silencing is generally considered to be a gene knockdown mechanism, and common methods for silencing genes can be RNAi.
- endogenous refers to any substance derived from or produced inside an organism, cell, tissue, or system.
- exogenous refers to any substance introduced from or produced outside an organism, cell, tissue, or system.
- antisense RNA generally refers to a single-stranded RNA complementary to the transcription product mRNA (messenger RNA). Antisense RNA can inhibit gene expression by binding to mRNA. For example, the binding of antisense RNA to target mRNA causes the double-stranded RNA molecule to increase its sensitivity to RNase III and cause it to degrade; for example, antisense RNA binds to the upstream non-coding region of mRNA, thereby directly inhibiting the translation of target mRNA .
- siRNA generally refers to the abbreviation of Small interfering RNA (small interfering RNA) or short in-terfering RNA (short interfering RNA).
- siRNA is a type of double-stranded non-coding RNA molecule with a length of about 18-28 base pairs, which can cause degradation of mRNA through complementary binding with mRNA, thereby interfering with the expression of specific genes.
- siRNA may be a product obtained by treating long double-stranded RNA or shRNA with Dicer enzyme.
- siRNA enters the cell to form an RNA-induced silencing complex (RISC) with other proteins, the sense strand is degraded, and the antisense strand can be combined with a complementary targeting sequence to achieve gene silencing.
- RISC RNA-induced silencing complex
- shRNA usually refers to the abbreviation of short hairpin RNA, that is, “short hairpin RNA”.
- shRNA usually includes two short inverted repeats, separated by a loop sequence in the middle, forming a hairpin structure.
- 5-6 T bases can be included as the transcription terminator of RNA polymerase III.
- shRNA can enter the cell via a viral vector or plasmid, and be transcribed under the action of polymerase II or polymerase III.
- the transcription product is exported from the nucleus (usually via Exportin 5) and then processed by Dicer for delivery.
- RISC the sense strand is degraded, and the antisense strand can be combined with the complementary targeting sequence to achieve gene silencing.
- CRISPR/Cas system generally refers to a group of molecules including RNA-guided nucleases or other effector molecules and gRNA molecules, which can direct and implement RNA-guided nucleases or other effector molecules.
- the nucleic acid is modified at the target sequence, for example to cause degradation of the target sequence.
- the CRISPR system comprises gRNA and Cas protein, for example, Cas9 protein.
- a system containing Cas9 or a functional mutant thereof is referred to as the "Cas9 system” or "CRISPR/Cas9 system” in this application.
- gRNA molecules and Cas molecules can be complexed to form a ribonucleoprotein (RNP) complex.
- RNP ribonucleoprotein
- gRNA molecule or “guide RNA”, “guide RNA”, “guide RNA”, “guide RNA molecule”, and “gRNA” are used interchangeably, and generally refer to the ability to promote specific guidance RNA guidance Nuclease or other effector molecules (generally complexed with gRNA molecules) to nucleic acid molecules on the target sequence.
- the hybridization of a part of the gRNA with DNA for example, through the gRNA steering domain
- the binding of a part of the gRNA molecule to RNA-guided nucleases or other effector molecules for example, at least through gRNAtracr
- the gRNA molecule is composed of a single continuous polynucleotide molecule, referred to herein as a "single guide RNA” or “sgRNA” or the like.
- the gRNA molecule is composed of multiple (for example, two) polynucleotide molecules that can associate themselves (generally by hybridization), and are referred to herein as “dual guide RNA” or “dgRNA” or the like.
- Cas protein generally refers to the enzyme responsible for cutting DNA in the CRISPR/Cas system. It can include enzymes from type I, II, and III CRISPR/Cas systems. For example, Cas3, Cas9, Cas10.
- Cas9 protein generally refers to the enzyme from the bacterial type II CRISPR/Cas system responsible for cutting DNA. Cas9 can include wild-type proteins and functional mutants thereof.
- locus is also called a gene locus or locus, which refers to a fixed position on a chromosome, such as where a certain gene is located.
- the arrangement position of the locus in the genome is called a genetic map.
- CAR chimeric antigen receptor
- TAA tumor associated antigen
- ITAM immunoreceptor tyrosine-based activation motifs
- binding domain generally refers to (specifically) binding to a given target epitope or a given target site on a target molecule (for example an antigen), or to the given target epitope or A given target site interacts, or recognizes the given target epitope or the domain of the given target site.
- the term "specific binding” generally refers to a measurable and reproducible interaction, such as the binding between a target and an antibody, which can determine the target in the presence of a heterogeneous population of molecules (including biomolecules) The presence.
- an antibody that specifically binds a target is an antibody that binds to the target with greater affinity, affinity, easier, and/or longer duration than it binds to other targets.
- the antibody specifically binds to an epitope on a protein that is conserved among proteins of different species.
- specific binding may include but does not require exclusive binding.
- transmembrane domain generally refers to a polypeptide or protein that is encoded by at least one exon including an extracellular region, a transmembrane region, and an intracellular region at the DNA level.
- the transmembrane domain generally contains three different structural regions: the N-terminal extracellular region, the conserved transmembrane stretch region in the middle, and the C-terminal cytoplasmic region.
- the transmembrane domain may also contain intracellular or cytoplasmic regions.
- the term "hinge region” generally refers to a region between the binding domain and the transmembrane domain in the CAR structure.
- the hinge region is usually derived from the IgG family, such as IgG1 and IgG4, and some are derived from IgD and CD8.
- the hinge region has a certain degree of flexibility, which affects the space constraint between the CAR molecule and its specific target, and then affects CAR T Contact between cells and tumor cells.
- costimulatory usually refers to the source of lymphocyte activation of the second signal, usually by the surface costimulatory molecules of immune cells involved in adaptive immunity (T cell/B cell or antigen presenting cell/T cell) And its receptor interaction.
- T cell/B cell or antigen presenting cell/T cell adaptive immunity
- costimulatory molecules of immune cells involved in adaptive immunity T cell/B cell or antigen presenting cell/T cell
- the complete activation of T cells depends on the effects of dual signals and cytokines.
- the first signal of T cell activation comes from the specific binding of its receptor TCR and antigen, that is, T cell recognition of the antigen
- the second signal of T cell activation comes from costimulatory molecules, that is, the costimulatory molecules of antigen-presenting cells and the surface of T cells The interaction of the corresponding receptors.
- costimulatory domain generally refers to the intracellular part of the corresponding receptor of the costimulatory molecule, which can transmit a costimulatory signal (also referred to as a second signal).
- a costimulatory signal also referred to as a second signal.
- CD137 or other costimulatory molecule receptors
- costimulatory domain from CD137 can be activated after the extracellular binding domain in the CAR structure binds to the corresponding antigen, and transduce costimulatory signals.
- the term "primary signal transduction domain” generally refers to an amino acid sequence capable of generating signals that promote the immune effector function of CAR-containing cells, such as CAR-T cells.
- immune effector functions in, for example, CAR-T cells may include cytolytic activity and auxiliary activity, including secretion of cytokines.
- the primary signaling domain transduces effector function signals and directs cells to perform specialized functions.
- the entire primary signaling domain can be used, in many cases, it is not necessary to use the entire chain. In terms of using truncated portions of the primary signaling domain, such truncated portions can be used to replace the complete chain as long as it can transduce effector function signals.
- the term primary signaling domain is therefore intended to include any truncated portion of the intracellular signaling domain sufficient to transduce effector function signals.
- tumor antigen generally refers to molecules (such as proteins, sugars, or lipids) that are expressed intact or as fragments on the surface of tumor cells and can be used to preferentially guide drugs to tumor cells.
- the tumor antigen may be a marker expressed by both normal cells and cancer cells, for example, a lineage marker, for example, CD19 on B cells.
- the tumor antigen may be a cell surface molecule that is overexpressed in tumor cells, for example, a 1-fold over-expression, a 2-fold over-expression, and a 3-fold or more over-expression compared to normal cells.
- the cell surface molecules are abnormally expressed in tumor cells, for example, molecules that contain deletions, additions, or mutations compared to corresponding molecules expressed on normal cells.
- tumor antigens may be exclusively expressed on the surface of tumor cells intact or as fragments (e.g., MHC/peptide), and are not synthesized or expressed on the surface of normal cells.
- the CAR in the present application may include an antigen-binding domain that binds to a peptide presented by MHC, such as an antibody or antibody fragment.
- MHC major histocompatibility complex
- TCR T cell receptors
- the MHC class I complex is constitutively expressed by all nucleated cells.
- Virus-specific and/or tumor-specific peptide/MHC complexes can be used for unique classes of cell surface targets for immunotherapy. (See, for example, Sastry et al., J Virol.
- the term "monoclonal antibody” generally refers to an antibody obtained from a population of substantially homogeneous antibodies. That is, the individual antibodies that make up the population are the same, except for possible naturally occurring mutations and/or post-translational modifications (such as isomerization, amidation) that may be present in very small amounts. Monoclonal antibodies are highly specific and are directed against a single antigenic site. Unlike typical polyclonal antibody preparations that contain different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the advantage of monoclonal antibodies is that they are synthesized from hybridoma cultures and are not contaminated by other immunoglobulins. The modifier "monoclonal" indicates the characteristics of an antibody obtained from a substantially homogeneous antibody population and should not be interpreted as requiring the production of antibodies by any specific method.
- polyclonal antibody generally refers to a composition of different antibody molecules.
- Polyclonal antibodies can bind or react with multiple different specific epitopes on the same or different antigens.
- the antigen-specific variability of a polyclonal antibody is located in the variable regions of the individual antibodies constituting the polyclonal antibody, for example, in the complementarity determining regions (CDR) 1, CDR2, and CDR3 regions.
- CDR complementarity determining regions
- polyclonal antibodies can be prepared by immunizing animals with the target sFGFR or part thereof.
- polyclonal antibodies can be prepared by mixing multiple monoclonal antibodies having the specificity of the desired target sFGFR.
- human antibody generally refers to an antibody having variable and constant regions derived from human germline immunoglobulin sequences.
- Human antibodies are well known in the prior art (see, for example, van Dijk, M.A. and van de Winkel, J.G., Curr. Opin. Chem. Biol. 5 (2001) 368-374). It is also possible to generate human antibodies in transgenic animals (e.g., mice) that, after immunization, can generate a complete repertoire or selection of human antibodies without endogenous immunoglobulin production (e.g., Jakobovits, A., etc., Proc. Natl. Acad. Sci. USA 90 (1993) 2551-2555; Jakobovits, A.
- Human antibodies can also be generated in phage display libraries (e.g. Hoogenboom, HR and Winter, G., J. Mol. Biol. 227 (1992) 381-388; Marks, JD, etc., J. Mol. Biol. 222 (1991) 581-597).
- the term "human antibody” can also include antibodies modified in the constant region.
- humanized antibody generally refers to an antibody containing heavy and light chain variable region sequences from non-human species (such as mouse), but at least a portion of the VH and/or VL sequences have been The changes are similar to human germline variable sequences.
- the term “humanized antibody” is a framework that can immunospecifically bind to a related antigen and includes a framework (FR) region substantially having the amino acid sequence of a human antibody and a complementarity determining region (CDR) substantially having the amino acid sequence of a non-human antibody.
- FR framework
- CDR complementarity determining region
- substantially in the context of CDR means that the amino acid sequence of the CDR is at least 80%, for example at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to the amino acid sequence of the non-human antibody CDR.
- a humanized antibody basically contains at least one and usually two variable domains (Fab, Fab', F(ab')2, FabC, Fv), wherein all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin
- the CDR regions and all or substantially all of the framework regions are framework regions with consensus sequences of human immunoglobulins.
- the humanized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc), usually that of a human immunoglobulin.
- single domain antibody generally refers to a type of antibody that lacks the light chain of the antibody but contains the variable region of the heavy chain. Because of its small molecular weight, it is also called Nanobody. Single-domain antibodies were first found in camelid animals, and similar antibodies were also found in chondrophytes such as nurse sharks, great star sharks, and rays. For example, antibodies that lack both the light chain of traditional antibodies and the CH1 region of the heavy chain constant region are called heavy chain antibodies (HcAb). HcAbs are commonly found in various camelid animals.
- a heavy chain antibody called Ig new antigen receptor, or IgNAR for short is composed of two identical heavy chains, and the heavy chain contains 5 constant regions and 1 variable region.
- the variable region of a heavy chain antibody is only composed of the variable region of an antibody heavy chain. Similar to the Fab of a traditional antibody, this variable region can specifically bind to an antigen, so the heavy chain antibody can perform the same function as a traditional antibody.
- tumor generally refers to neoplasms or solid lesions formed by abnormal cell growth.
- the tumor can be a solid tumor or a non-solid tumor.
- a tangible mass that can be detected by clinical examinations such as X-ray film, CT scan, B-ultrasound, or palpation can be called a solid tumor.
- X-ray, CT scan, B-ultrasound and palpation cannot Tumors seen or palpated, such as leukemia, can be called non-solid tumors.
- CD namely cluster of differentiation, also called cluster of differentiation
- CD molecules have many uses, and are usually used as important receptors or ligands for cells. Some CDs can participate in the signal cascade of cells to change the behavior of cells. Some CD proteins have nothing to do with cell signal transduction, but have other functions, such as cell adhesion. As of April 21, 2016, the total number of CD molecules in humans is 371.
- the term "pharmaceutically acceptable carrier” generally refers to a pharmaceutically acceptable substance, composition or vehicle involved in carrying, storing, transporting, or administering cell preparations.
- a pharmaceutically acceptable carrier may include a pharmaceutically acceptable salt, wherein the term “pharmaceutically acceptable salt” includes a salt of the active compound prepared using a relatively non-toxic acid or base, depending on the characteristics of the cells described in the present application , Such as sodium chloride.
- Pharmaceutically acceptable carriers may also include organic acids (such as lactic acid), biologically active substances (such as polypeptides, antibodies, etc.), antibiotics (such as penicillin, streptomycin), and the like.
- Pharmaceutically acceptable carriers may also include hydrogels, such as hydrogels containing polyacrylamide.
- Pharmaceutically acceptable carriers may include storage solutions, cryopreservation solutions, injection solutions, etc. that can be used for cells. Generally speaking, the pharmaceutically acceptable carrier can maintain the activity of the cells it carries and does not hinder its therapeutic efficacy; the pharmaceutically acceptable carrier can also help the storage, transportation, and cell recovery of the cells. Proliferation, migration, and suitable for clinical applications.
- composition generally refers to a composition suitable for administration to patients, human patients.
- the composition described in this application may comprise the immune effector cells described in this application, and optionally a pharmaceutically acceptable carrier.
- the acceptable ingredients of the composition are non-toxic to the recipient at the dosage and concentration used.
- the compositions of the present application include, but are not limited to, liquid, frozen and lyophilized compositions.
- allogeneic therapy generally refers to a treatment method in which organs, tissues, cells, etc. not derived from the subject or patient are administered to the subject or patient to achieve the purpose of treatment.
- the term "about” generally refers to a range of 0.5%-10% above or below the specified value, such as 0.5%, 1%, 1.5%, 2%, 2.5%, above or below the specified value. Variation within the range of 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%.
- the present application provides a modified immune effector cell, wherein the expression and/or the expression and/or the activity of the TRAC gene and the HLA-A gene are compared with the expression and/or activity of the corresponding gene in the corresponding cell without the modification.
- the activity is down-regulated, the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or activity of the CIITA gene is not down-regulated.
- the present application also provides a method for preparing the modified immune effector cell described in the present application, which includes the following steps: and the expression and/or activity of the corresponding gene in the corresponding cell without the modification.
- the modification causes the expression and/or activity of two genes to be down-regulated, wherein the two genes are composed of the TRAC gene and the HLA-A gene.
- the immune effector cells may include plasma cells, T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells and/or bone marrow-derived phagocytes.
- NK natural killer
- NKT natural killer T
- the plasma cells refer to effector B cells/antibody secreting cells, which may include primitive plasma cells, young plasma cells, Russell bodies, Dutcher bodies, flame cells, and the like.
- the B cell refers to all B cell types except plasma cells, for example, pre-B cells, immature B cells, mature B cells, activated B cells, and the like.
- the T cells may include: helper T cells (Th), which can assist humoral immunity and cellular immunity; suppressor T cells (Ts) ), the suppressor T cells can inhibit cellular immunity and humoral immunity; effector T cells (Te), which can release lymphokines; cytotoxic T cells (Tc), so The cytotoxic T cells can kill target cells; Delayed type hypersensitivity T cells (Td), which can participate in the effect of type IV allergies; Amplified T cells (Ta) The amplified T cells (Ta) can act on Th and Ts to expand the immune effect; primitive or natural T cells (Virgin or Natural T cells) can differentiate into effector T cells or after contact with antigens. Memory T cell; Memory T cell (Memory T cell, Tm), the memory T cell can memory specific antigen stimulation.
- Th helper T cells
- Ts suppressor T cells
- Tc cytotoxic T cells
- Tc cytotoxic T cells
- Ta The amplified T cells (Ta) can act on Th and Ts to
- the cytotoxic T cell may have a cell surface marker CD8+.
- the helper T cell may have a cell surface marker CD4+.
- the corresponding cells without the modification may include wild-type cells and/or artificially modified cells.
- the wild-type cells may include naturally-occurring or naturally-derived cells, such as plasma cells, T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells and/or cells isolated from the human body.
- the human body is a healthy human body.
- the healthy human body may include those without tumors or immune system related diseases or disorders.
- the artificial modification may be an artificial modification that does not use the TRAC gene, HLA-A gene, B2M gene, and CIITA gene as the recognition site/target.
- the artificial modification does not affect the TRAC gene, HLA gene.
- -A gene, B2M gene and CIITA gene expression and/or activity said not affecting the expression and/or activity of TRAC gene, HLA-A gene, B2M gene and CIITA gene refers to the separation from the human body or from the Compared with corresponding cells obtained from human precursor cells or pluripotent cells that have not been further artificially modified, the expression and/or activity of TRAC gene, HLA-A gene, B2M gene and CIITA gene remain unchanged. The expression and/or activity is not completely the same.
- the mRNA quantitative analysis of the TRAC gene, HLA-A gene, B2M gene, and CIITA gene in the two is not significant.
- Sexual difference P>0.05
- using conventional technical means in the field to detect, compared with the two TRAC gene, HLA-A gene, B2M gene and CIITA gene corresponding polypeptide/protein quantitative analysis does not have significant Sexual difference (P>0.05).
- the artificially modified cells may include CAR-T cells; for example, the CAR-T cells may include CAR-T cells whose CAR molecules contain binding domains targeting the following molecules: CD19, PSCA, CD123, CD20, CEA , FAP, CD133, EGFR, EGFRVIII, BCMA, PSMA, Her2, CA125, EphA2, C-met, L1CAM, VEGFR, CS1, ROR1, EC, NY-ESO-1, MUC1, LewisY, GPC3, GD2, DLL3, CD99 , 5T4, CD22, CD30, CD33, CD138 and/or CD171.
- TRAC gene HLA-A gene, B2M gene and CIITA gene
- the expression and/or activity of the TRAC gene and the HLA-A gene are down-regulated, the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or the CIITA gene The activity was not down-regulated.
- the expression and/or activity of two genes are down-regulated compared with the corresponding wild-type cells, wherein the two genes are composed of TRAC gene and HLA-A gene.
- the down-regulating the expression level and/or activity of the gene includes down-regulating the expression and/or activity of the nucleic acid molecule encoding the gene; and/or the expression and/or the protein product encoded by the gene Activity is down-regulated.
- the protein product may include a polypeptide.
- the expression and/or activity of the TRAC gene and HLA-A gene are down-regulated or the down-regulation of the expression and/or activity of the TRAC gene and HLA-A gene in the immune effector cell may include and Compared with the modified corresponding cell, the modification changes the nucleotide sequence structure of the TRAC gene and the HLA-A gene.
- the nucleotide sequence may include a coding region or a non-coding region, such as a cis-regulatory element sequence, an exon sequence, and the cis-regulatory element sequence may include a promoter.
- the changes may include partial or complete deletion of sequences, insertion of foreign fragments, base site mutations, etc.
- the inserted foreign fragments may replace or destroy the sequence structure of the TRAC gene and the HLA-A gene, so that it cannot be normal.
- the base site mutations may include frameshift mutations, missense mutations, nonsense mutations, and the like.
- the alteration may include chemical group modification of the nucleotide sequence, such as methylation and the like.
- the changes in the structure of the nucleotide sequence can be detected by gene sequencing, such as Sanger sequencing, sulfite sequencing, and the like.
- the expression and/or activity of the TRAC gene and HLA-A gene are down-regulated or the down-regulation of the expression and/or activity of the TRAC gene and HLA-A gene in the immune effector cell can also include the Compared with the modified corresponding cells, the modification reduces the mNNA content of the TRAC gene and the HLA-A gene.
- the mRNA content can be obtained by experimental methods and biostatistics methods well known to those skilled in the art, such as molecular probe in situ hybridization, real-time fluorescent quantitative PCR (qPCR, RT-PCR), and the real-time fluorescent quantitative PCR may include SYBR Green method, TaqMan method, two-hybrid probe method, molecular beacon method.
- the detection result of the mRNA content allows unavoidable errors in experiments or statistics, and the errors may be well-known in the art.
- the error may be in the range of ⁇ 10%, for example, ⁇ 8%, ⁇ 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%.
- the mNNA content is reduced by at least 30%, such as 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, for example, mNNA of TRAC gene and HLA-A gene cannot be detected in the modified immune effector cells.
- the expression and/or activity of the TRAC gene and HLA-A gene are down-regulated or the down-regulation of the expression and/or activity of the TRAC gene and HLA-A gene in the immune effector cell can also include the Compared with the modified corresponding cells, the modification reduces the content of polypeptides expressed by the TRAC gene and the HLA-A gene.
- the polypeptide refers to a polypeptide that has the same structure and function as the polypeptide produced by the expression of the TRAC gene and the HLA-A gene in the corresponding cell without the modification, and is produced by changes in the nucleotide sequence of the TRAC gene and the HLA-A gene Peptides with changed functions and structures are not in the comparison.
- the polypeptide content can be obtained by experimental methods and biostatistical methods known to those skilled in the art, such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), cell immunofluorescence staining, Western blotting (Western blotting, WB).
- ELISA enzyme-linked immunosorbent assay
- WB Western blotting
- the detection result of the polypeptide content allows unavoidable errors in experiments or statistics, and the errors may be well-known in the art.
- the error may be in the range of ⁇ 10%, for example, ⁇ 8%, ⁇ 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%.
- the polypeptide content is reduced by at least 30%, such as 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, for example, the polypeptides expressed by the TRAC gene and the HLA-A gene cannot be detected in the modified immune effector cells.
- the expression and/or activity of the TRAC gene and HLA-A gene are down-regulated or the down-regulation of the expression and/or activity of the TRAC gene and HLA-A gene in the immune effector cell may refer to knockout Or knock down the expression of the TRAC gene and HLA-A gene or perform other operations that disrupt the function of the TRAC protein and HLA-A protein.
- the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or activity of the CIITA gene is not down-regulated, or the expression and/or activity of the B2M gene is not down-regulated, and the CIITA is not down-regulated
- the expression and/or activity of the gene may include that the mNNA content of the B2M gene and the CIITA gene does not decrease compared with the corresponding cell without the modification.
- the mRNA content can be obtained by experimental methods and biostatistics methods well known to those skilled in the art, such as molecular probe in situ hybridization, real-time fluorescent quantitative PCR (qPCR, RT-PCR), and the real-time fluorescent quantitative PCR may include SYBR Green method, TaqMan method, two-hybrid probe method, molecular beacon method.
- qPCR real-time fluorescent quantitative PCR
- RT-PCR real-time fluorescent quantitative PCR
- the detection result of the mRNA content allows unavoidable errors in experiments or statistics, and the errors may be well-known in the art.
- the error may be in the range of ⁇ 10%, for example, ⁇ 8%, ⁇ 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%.
- the non-decreasing of the mNNA content may include an increase or no change in the content, and the constant may include that the corresponding mRNA quantitative analysis of the B2M gene and the CIITA gene does not have a significant difference between the two compared (P>0.05).
- the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or activity of the CIITA gene is not down-regulated, or the expression and/or activity of the B2M gene is not down-regulated, and the CIITA is not down-regulated
- the expression and/or activity of the gene may include that the content of the polypeptide expressed by the B2M gene and the CIITA gene does not decrease compared with the corresponding cell without the modification.
- the polypeptide refers to a polypeptide that has the same structure and function as the polypeptide produced by the expression of the B2M gene and the CIITA gene in the corresponding cell without the modification.
- the polypeptide content can be obtained by experimental methods and biostatistical methods known to those skilled in the art, such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), cell immunofluorescence staining, Western blotting (Western blotting, WB).
- ELISA enzyme-linked immunosorbent assay
- WB Western blotting
- the detection result of the polypeptide content allows unavoidable errors in experiments or statistics, and the errors may be well-known in the art.
- the error may be in the range of ⁇ 10%, for example, ⁇ 8%, ⁇ 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%.
- the non-decreasing of the content of the polypeptide may include an increase or no change in the content, and the change may include that the quantitative analysis of the corresponding polypeptides of the B2M gene and the CIITA gene does not have a significant difference between the two compared (P>0.05).
- the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or activity of the CIITA gene is not down-regulated, or the expression and/or activity of the B2M gene is not down-regulated, and the CIITA is not down-regulated
- the expression and/or activity of the gene may include not performing artificial intervention on the corresponding cell without the modification for the mRNA and/or polypeptide encoded by the CIITA gene and the B2M gene, the CIITA gene and the B2M gene, for example, the artificial intervention
- the intervention may include the introduction of nucleotide molecules or other compounds that can target the CIITA gene and the B2M gene or the mRNA molecules encoded by the CIITA gene and the B2M gene or their encoded mRNA molecules and change their structure or content into the corresponding cells without the modification.
- the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or activity of the CIITA gene is not down-regulated, or the expression and/or activity of the B2M gene is not down-regulated, and the CIITA is not down-regulated
- the expression and/or activity of the gene may include that the nucleotide sequence structure of the B2M gene and the CIITA gene has not changed compared with the corresponding cell without the modification, and the nucleotide sequence structure has not changed.
- Gene sequencing tests such as Sanger sequencing, sulfite sequencing, etc.
- the unaltered structure of the nucleotide sequence may include no artificial changes, and may also include naturally occurring changes that do not affect its function.
- the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or activity of the CIITA gene is not down-regulated, or the expression and/or activity of the B2M gene is not down-regulated, and the CIITA is not down-regulated
- the expression and/or activity of the gene may mean that no modification is performed targeting the B2M gene or the protein encoded by the CIITA gene or the protein encoded by the CIITA gene.
- the expression level and/or activity of at most two alleles in the HLA-A gene are down-regulated.
- the two alleles may be a pair of alleles of the HLA-A gene in the immune effector cell; for example, the expression level and/or activity of one allele in the HLA-A gene Down.
- the TRAC gene may include the gene shown in HGNC:12029 and all allele types thereof.
- the TRAC gene and all allele types thereof may include the TRAC gene type that can be present in the immune effector cell.
- the TRAC gene may include the nucleotide sequence shown in SEQ ID No. 55.
- the TRAC gene may include a nucleotide sequence derived from a human and having 80% or more homology with the nucleotide sequence shown in SEQ ID No. 55, for example, 85% or more, 90% or Above, 95% or above, 96% or above, 97% or above, 98% or above, 99% or above.
- the HLA-A gene may include the gene shown in HGNC:4931 and all allele types thereof.
- the HLA-A gene may include all HLAs named by the WHO HLA Factor Nomenclature Committee included in IMGT/HLA database version 3.38.0 (https://www.ebi.ac.uk/ipd/imgt/hla/) -A allele type, the HLA-A allele type and its sequence information disclosed in IMGT/HLA database version 3.38.0 are incorporated herein by reference.
- the HLA-A allele may include A*02, A*24, A*01, A*03, A*32, A*11, A*26, A*68, A*23, A* 29. Any one or more of A*31, A*33, A*25, A*43, A*74, A*30, A*69.
- the HLA-A allele may include A*02:01, A*03:01, A*01:01, A*24:02, A*68:01, A*11:01, A* Any one of 31:01:02, A*29:02, A*32:01, A*26, A*23:01, A*30:02, A*25:01, A*33:03 Or multiple.
- the HLA-A allele may include A*02:01:01, A*01:01:01, A*03:01:01, A*24:02:01, A*11:01: 01, A*32:01:01, A*29:02:01, A*31:01:02, A*23:01:01, A*26:01:01, A*68:01:02, A*30:01:01, A*68:02:01, A*25:01:01, A*68:01:01,
- the HLA-A allele may include A*02, A*30, A*03, A*01, A*24, A*32, A*68, A*11, A*26, A* 23. Any one or more of A*31 and A*25.
- the HLA-A allele may include A*02:01, A*03:01, A*24:02, A*01:01, A*11:01, A*26:01, A* Any one or more of 25:01, A*68:01, A*32:01, A*31:01.
- the HLA-A allele may include A*24, A*33, A*02, A*11, A*26, A*31, A*01, A*24:02, A*02: 01, A*33:03, A*11:01, A*26:01, A*02:06, A*31:01:02, A*26:03, A*26:02, A*02: Any one or more of 07, A*01:01, A*02:10, A*03:01.
- the HLA-A allele may include A*02, A*24, A*33, A*11, A*26, A*31, A*30, A*03, A*01, A* 32, A*29, A*68, A*23, A*25, A*34, A*36, A*43, A*66, A*74.
- the HLA-A allele may include A*24:02, A*33:03, A*02:01, A*11:01, A*02:01, A*31:01, A* 26:01, A*02:07, A*30:01, A*26:02, A*01:01,
- the HLA-A allele may include A*02:01, A*11:01, A*24:02, A*30:01, A*26:01, A*23:01, A* 02:07, A*02:06, A*03:01, A*01:01, A*31:01:02, A*33:03, A*32:01, A*68:01, A* Any one or more of 02:03 and A*02:05.
- the HLA-A allele may include A*03:01, A*02:01, A*23:01, A*01:01, A*30:02, A*30:01, A* 33:03, A*29:02, A*74:01, A*36:01, A*24:02, A*02:02, A*68:01, A*68:02, A*34: Any one or more of 02, A*66:02, A*31:01:02, A*32:01, A*02:05, A*66:01, A*26:01.
- the HLA-A allele may include any one or more of A*02, A*11, A*24, A*30, A*33, A*03, A*01, A*26 Kind.
- the HLA-A allele may include A*11:01, A*24:02, A*02:01, A*02:07, A*33:03, A*02:06, and A* Any one or more of 30:01.
- the HLA-A alleles may include HLA-A*02:01:01:01, HLA-A*11:01:01:01, HLA-A*24:02:01, HLA-A* 30:01:01:01, HLA-A*33:01:01:01, HLA-A*03:01:01:01, HLA-A*01:01:01:01, HLA-A*26: Any one or more of 01:01:01.
- the HLA-A gene may include a nucleic acid sequence as shown in any one of SEQ ID NOs. 56-63.
- the HLA-A gene may include a nucleotide sequence derived from a human and having 80% or more homology with the nucleic acid sequence shown in any one of SEQ ID NO. 56-63, for example, 85% Or above, 90% or above, 95% or above, 96% or above, 97% or above, 98% or above, 99% or above.
- the modification may include gene knockout and/or gene silencing.
- the modification may include deletion of all or part of a gene, gene mutation and/or gene silencing.
- the gene knockout may include deletion of all or part of the gene, gene mutation, and the like.
- the gene may include the HLA-A gene and/or the TRAC gene.
- the modification may include knocking out any one of the two TRAC alleles and knocking out any one of the two HLA-A alleles in the immune cell.
- the modification may include that two TRAC alleles in the immune cell are knocked out and any one of the two HLA-A alleles is knocked out.
- the modification may include any one of the two TRAC alleles being knocked out and the two HLA-A alleles being knocked out.
- the modification may include two TRAC alleles being knocked out and two HLA-A alleles being knocked out.
- the deletion of the partial fragment of the gene may include the deletion of ⁇ 1 exon sequence.
- the genetic mutation may include a change in base pair composition or arrangement order, which usually can lead to, for example, missense mutations, frameshift mutations, and/or nonsense mutations.
- the missense mutation usually refers to a change in a certain base pair, which changes a codon encoding one amino acid to a codon encoding another amino acid, thereby changing the corresponding amino acid constituting the protein.
- the frameshift mutation usually refers to the insertion or deletion of one or several bases that are not an integer multiple of 3 in the DNA strand, resulting in a change in the coding codon.
- the nonsense mutation usually means that a certain base pair change causes a codon encoding an amino acid to become a terminator, and protein synthesis is terminated early when the site is reached.
- the change in the composition or arrangement order of the base pairs may include a single nucleotide or base change (also called a point mutation) and/or a polynucleotide or base change.
- the single nucleotide or base change may include the replacement of one base or nucleotide by another base or nucleotide, and the insertion or deletion of one base.
- the polynucleotide or base change may include the loss of a base sequence, the insertion of a base sequence, and/or the rearrangement of a base sequence.
- the base sequence may be a part of any exon/or intron in the gene.
- the rearrangement may include repetition, inversion, translocation, etc. of the base sequence.
- the gene silencing may include transcriptional gene silenc-ing (TGS) and/or post-transcriptional gene silen-cing (PTGS).
- TGS transcriptional gene silenc-ing
- PTGS post-transcriptional gene silen-cing
- the silencing at the transcriptional level may include methylation of DNA molecules to inhibit DNA, such as promoter sequence methylation; the post-transcriptional gene silencing may include the specific intervention of the target RNA after the gene is transcribed. Changes in gene expression. For example, RNA interference (RNAi) reduces mRNA levels.
- RNA interference RNA interference
- the modification may include a technique or method that uses homologous recombination to replace an exogenous nucleotide sequence with an endogenous normal gene, thereby inactivating the endogenous normal gene.
- the exogenous nucleotide sequence may be known.
- the exogenous nucleotide sequence may be a partial fragment of the endogenous normal gene; for example, the exogenous nucleotide sequence may include a homology arm 1 from 5'to 3'in turn.
- the nucleotide sequence to be inserted may include a reporter gene, a non-coding sequence, or a variant sequence of an endogenous normal gene.
- the modification may include administering one or more substances selected from the group consisting of antisense RNA, siRNA, shRNA, and CRISPR/Cas9 system to the immune effector cell.
- the antisense RNA may be a single-stranded RNA complementary to the transcription product mRNA (messenger RNA).
- the complementarity is that at least 60% of the nucleic acid sequence of the antisense RNA is complementary to the mRNA, such as at least 70%, such as at least 80%, such as at least 90%, such as 100% complementary.
- the binding of the antisense RNA to the target mRNA causes the sensitivity of the double-stranded RNA molecule to RNase III to increase, thereby degrading it.
- the antisense RNA binds to the upstream non-coding region of the mRNA, thereby inhibiting the translation of the target mRNA.
- the antisense RNA is artificially prepared.
- the antisense RNA cannot form a short hairpin structure.
- the antisense RNA may include the nucleotide sequence described in any one of SEQ ID NO: 93-96.
- the siRNA may be a type of double-stranded non-coding RNA molecule with a length of about 18-28 base pairs.
- the siRNA can cause degradation of mRNA through complementary binding to mRNA.
- the length of the siRNA may be 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 base pairs.
- the siRNA is artificially prepared.
- the siRNA is obtained by treating long double-stranded RNA or shRNA in a cell with Dicer enzyme.
- the shRNA refers to a type of RNA that can form a short hairpin structure.
- the shRNA may include two short inverted repeats, and a loop sequence located between the two short inverted repeats.
- At least 18 consecutive nucleic acid sequences in the shRNA are capable of complementary binding to the target mRNA, such as at least 19, such as at least 20, such as at least 21, such as at least 22, such as at least 23, such as at least 24 , Such as at least 25, such as at least 26.
- the shRNA does not include the sgRNA described in this application.
- the modification may include administering the CRISPR/Cas system to the immune effector cells.
- the CRISPR/Cas system may include guide RNA (gRNA) and Cas enzyme.
- the gRNA may include crRNA and tracrRNA.
- the gRNA can be called dgRNA (dual molecule gRNA), when the crRNA and the tracrRNA are located in the same nucleotide molecule
- the gRNA may be referred to as sgRNA (single molecule gRNA).
- the CRISPR/Cas system may include gRNA nucleic acid sequence and Cas protein.
- the RNP complex formed by gRNA nucleic acid sequence and Cas protein may include gRNA nucleic acid sequence and Cas protein.
- the CRISPR/Cas system may also include a nucleic acid sequence encoding the gRNA and a nucleic acid sequence encoding the Cas protein.
- the nucleic acid sequence encoding the gRNA and the nucleic acid sequence encoding the Cas protein may be placed in a plasmid, virus (for example, adenovirus, lentivirus, retrovirus) and other vectors commonly used in the field.
- virus for example, adenovirus, lentivirus, retrovirus
- the nucleic acid sequence encoding the gRNA and the nucleic acid sequence encoding the Cas protein may be located in the same vector or in different vectors.
- the nucleic acid sequence encoding tracrRNA and the sequence encoding crRNA may be located in the same vector or in different vectors.
- the promoters used to drive the expression of each coding sequence may be the same or different.
- the CRISPR/Cas system may include more than one guide RNA.
- Each guide RNA can contain different targeting sequences, allowing the CRISPR/Cas system to cleave more than one target sequence.
- one or more guide RNAs can have the same or different characteristics, such as activity or stability in the CRISPR/Cas complex.
- each guide RNA can be encoded on the same or different vectors.
- the promoters used to drive the expression of more than one guide RNA can be the same or different.
- the guide RNA includes a guide RNA that targets the HLA-A gene and the TRAC gene.
- the modification also includes the application of Cas enzyme to the cell.
- the Cas enzyme may include a Cas protein and a nucleic acid sequence encoding the Cas protein.
- the Cas protein may include at least one domain that interacts with a guide RNA (gRNA); for example, the Cas protein can be guided to a target sequence by the guide RNA; for example, the guide RNA interacts with the Cas protein and the target sequence.
- gRNA guide RNA
- the guide RNA provides specificity for targeted cleavage
- the Cas protein can be universal, pairing with different guide RNAs to cut different target sequences; for example,
- the Cas protein can cut single-stranded or double-stranded DNA; for example, the Cas protein can cut RNA; for example, the Cas protein can cut RNA/DNA; for example, the Cas protein includes at least one DNA binding domain and At least one nuclease domain; for example, the nuclease domain can be heterologous to the DNA binding domain; for example, the nuclease activity can be changed by modifying the Cas protein; for example, the Cas protein can be used for binding and Regulate the expression or activity of DNA; for example, the Cas protein may be a Cas nuclease.
- the CRISPR/Cas system may include type 1 or type 2 system components, including ribonucleic acid protein complexes (see, for example, Makarova et al., Nat Rev Microbiol, 13(11):722-36 (2015); Shmakov Et al., Molecular Cell, 60: 385-397 (2015).
- the type 2 CRISPR/Cas system has a single-protein effector.
- Cas proteins of type II, V, and VI can be single-protein, RNA guide nuclease, in this application It is referred to as "Type 2 Cas nucleases.”
- Type 2 Cas nucleases can include Cas9, Cpf1, C2c1, C2c2, and C2c3 proteins.
- Cas9 or Cpf1 protein can include RuvC Like nuclease domain or HNH-like nuclease domain, the Cpf1 sequence in Zetsche is introduced in this application in its entirety.
- the Cas protein can be from the type II CRISPR/Cas system (ie the Cas9 protein of the CRISPR/Cas9 system) or the type V CRISPR/Cas system (eg the Cpf1 protein).
- the Cas protein may be from a type 2 CRISPR/Cas system, such as Cas9 protein or Cpf1 protein.
- Class 2 Cas nuclease family proteins are enzymes with DNA endonuclease activity, which can be guided to cleave desired nucleic acid targets by designing appropriate guide RNAs described in this application.
- the components of the Type 2 CRISPR/Cas system can be from a type IIA, IIB, IIC, V or VI system.
- the Cas9 protein or its orthologs can be derived from the following exemplary species: Streptococcus pyogenes, Streptococcus thermophilus, Streptococcus sp., Staphylococcus aureus (Staphylococcus) aureus), Listeria in-nocua, Lactobacillus gasseri, Pasteurella novicida, Wolinella succinogenes, Neisseria meningitidis, Campylobacter jejuni, Pasteurella multocida, Fibrobacter succinogene, Rhodospirillum rubrum , Nocardiopsis rougevillei, Streptomyces pristinaespiralis, Streptomyces viridochromogenes, Streptosporangium roseum
- Lyngbya sp. Microcoleuschthonoplastes, Oscillatoria sp., Thermosiphoafricanus, Neisseriacinereal , Campylobacter lari or Corynebacterium diphtheria.
- the Cas9 protein may be derived from Streptococcus pyogenes; for example, the Cas9 protein may be derived from Streptococcus thermophilus; for example, the Cas9 protein may be derived from Staphylococcus aureus; for example, the Cpf1 protein may be derived from Tulare Pasteurella spp Porphyromonas macacae.
- the Cpf1 protein may be from the genus Aminococcus or Lachnospiraceae.
- the Cas9 protein may contain 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the Cas9 protein of Streptococcus pyogenes. % Homology of amino acid sequence.
- the Cas9 protein may include the amino acid sequence shown in SEQ ID NO:65.
- the exemplary nucleic acid sequence encoding the Cas9 protein is described in the following documents: Cong et al., SCIENCE 2013, 399(6121): 819-823; Wang et al., CELL 2013, 153(4): 910-918; Mali et al. , SCIENCE 2013,399(6121):823-826; Jinek et al.,SCIENCE 2012,337(6096):816-821.
- nucleotide sequence encoding the Cas9 protein is shown in SEQ ID NO: 64.
- the Cas9 protein may be modified.
- the modification may include amino acid substitutions, and other polypeptide fragments to form a fusion protein.
- the other polypeptide fragments may include PEST sequences, ubiquitin, polyubiquitin, and nuclear localization signal (NLS).
- the crRNA may include a targeting sequence, and the gRNA may target any target sequence through the targeting sequence of the crRNA.
- the degree of complementarity between the targeting sequence and the target sequence on the target nucleic acid molecule may be about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100%.
- the targeting sequence and the target sequence on the target nucleic acid molecule may be 100% complementary.
- the targeting sequence and the target sequence on the target nucleic acid molecule may contain at least one mismatch.
- the targeting sequence and the target sequence on the target nucleic acid molecule may contain 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mismatches.
- the targeting sequence and the target sequence on the target nucleic acid molecule may contain 1-6 mismatches.
- the targeting sequence and the target sequence on the target nucleic acid molecule may contain 5 or 6 mismatches.
- the targeting sequence and the target sequence on the target nucleic acid molecule do not contain mismatches.
- the length of the targeting sequence may depend on the CRISPR/Cas system and components used. For example, different Cas proteins from different bacterial species have different optimal targeting sequence lengths.
- the targeting sequence may include lengths of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or more than 50 nucleotides.
- the targeting sequence may comprise 18-24 nucleotides in length.
- the targeting sequence may comprise 19-21 nucleotides in length.
- the targeting sequence may comprise 20 nucleotides in length.
- the crRNA may also include a crRNA flagpole sequence
- the crRNA flagpole sequence may include any sequence that is complementary to tracrRNA and is sufficient to promote the formation of the CRISPR/Cas complex.
- the flagpole sequence may include all or part of a naturally occurring crRNA sequence (also referred to as a "marker” or "handle") that is complementary to a tracrRNA in the same CRISPR/Cas system.
- the flagpole sequence may include all or part of the repetitive sequence from the naturally occurring CRISPR/Cas system.
- the flagpole sequence may include a truncated or modified marker or handle sequence.
- the part of the tracrRNA that is complementary to the crRNA flagpole sequence may be referred to as a tracrRNA flagpole sequence.
- the degree of complementarity between the tracrRNA and the flagpole portion that hybridizes to the tracrRNA along the shorter of the two sequences can be about 40%, 50%, 60%, 70%, 80% or more.
- the tracrRNA and the flagpole part that hybridizes with tracrRNA is not 100% complementary along the shorter of the two sequences.
- the length of the crRNA flagpole sequence can depend on the CRISPR/Cas system or tracrRNA used.
- the crRNA flagpole sequence can comprise 10-50 nucleotides or more than 50 nucleotides in length.
- the crRNA flagpole sequence can contain 15-40 nucleotides in length.
- the crRNA flagpole sequence can contain 20-30 nucleotides in length.
- the crRNA flagpole sequence can contain 22 nucleotides in length.
- the length of the crRNA flagpole sequence can have no upper limit.
- the tracrRNA may include all or part of the wild-type tracrRNA sequence from the naturally-occurring CRISPR/Cas system.
- tracrRNA may comprise truncated or modified variants of wild-type tracrRNA.
- the length of tracrRNA can depend on the CRISPR/Cas system used.
- tracr RNA can contain lengths of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 70 , 80, 90, 100 or more than 100 nucleotides.
- tracr is at least 20 nucleotides in length.
- tracrRNA is at least 40 nucleotides in length.
- tracrRNA may contain secondary structures, such as one or more hairpin or stem-loop structures, or one or more raised structures.
- the guide RNA may include two RNA molecules, referred to herein as "dual guide RNA" or "dgRNA".
- dgRNA may include a first RNA molecule containing crRNA and a second RNA molecule containing tracrRNA. The first and second RNA molecules can form an RNA duplex through the base pairing between the flagpole sequence on crRNA and tracrRNA.
- the first RNA molecule from 5'to 3' may include a targeting sequence complementary to the target sequence, a crRNA flagpole sequence.
- the second RNA molecule from 5'to 3' may include a tracrRNA flagpole sequence complementary to a crRNA flagpole sequence, a nuclease binding sequence, for example, the nuclease binding sequence may be a Cas nuclease, for example, Cas9.
- the guide RNA may include a single RNA molecule, referred to as "single molecule gRNA" or "sgRNA".
- sgRNA may include tracrRNA, crRNA covalently linked to tracrRNA.
- crRNA and tracrRNA can be covalently linked via a linker nucleic acid sequence.
- a single-molecule gRNA may include a stem-loop structure formed by base pairing between the flagpole sequences on crRNA and tracrRNA.
- sgRNA is "Cas9sgRNA” that can mediate DNA cleavage by Cas9 protein.
- sgRNA is "Cpf1sgRNA” that can mediate DNA cleavage by Cpf1 protein.
- a single molecule of gRNA or sgRNA can include crRNA, loop, and tracrRNA from 5'to 3'.
- the crRNA from 5'to 3' may include a targeting sequence complementary to the target sequence, and a crRNA flagpole sequence.
- the tracrRNA from 5'to 3' may include a tracrRNA flagpole sequence complementary to a crRNA flagpole sequence, a nuclease binding sequence, for example, the nuclease binding sequence may be a Cas nuclease, for example, Cas9.
- a single molecule of gRNA or sgRNA from 5'to 3' may include a targeting sequence complementary to the target sequence, a crRNA flagpole sequence, a loop, a tracrRNA flagpole sequence complementary to a crRNA flagpole sequence, and a nuclease binding sequence.
- the gRNA may also contain modified nucleosides or nucleotides.
- changing e.g., replacing) one or more non-linked phosphate oxygen and/or one or more of the main chain phosphodiester bond connected to phosphate oxygen; e.g., changing, e.g., replacing) the component of ribose, for example, replacing the ribose 2'hydroxyl; for example, replacing the phosphate moiety with a dephosphorylated linker; for example, modifying or replacing a naturally occurring nucleobase; for example, replacing or modifying the phosphoribose backbone; for example, modifying the 3'end or 5'end of the oligonucleotide,
- removal, modification or replacement of terminal phosphate groups or conjugation moieties, capping or linker for example, 3'or 5'cap modification may include sugar and/or backbone modification); for example, modification or replacement of sugar.
- introducing the modified nucleoside or nucleotide increases the stability to nucleases.
- introducing the modified nucleoside or nucleotide reduces the innate immune response.
- the innate immune response includes a cellular response to foreign nucleic acids (including single-stranded nucleic acids), and may involve the expression and release of cytokines (especially interferons) and the induction of cell death.
- the modification may include administering sgRNA targeting the exon portion of the HLA-A gene to the immune effector cell.
- the sgRNA targeted to the exon part of the HLA-A gene may comprise the nucleotide sequence shown in any one of SEQ ID Nos. 16-54 and 91-92.
- the sgRNA targeting the exon part of the HLA-A gene may comprise a nucleus that is at least 70% homologous to the nucleotide sequence shown in SEQ ID No. 16-54, 91-92.
- the nucleotide sequence for example, at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%.
- the modification may include administering sgRNA targeting the exon portion of the TRAC gene to the immune effector cell.
- the sgRNA targeting the exon part of the TRAC gene may comprise the nucleotide sequence shown in any one of SEQ ID No. 1-15.
- the sgRNA targeting the exon part of the TRAC gene may comprise a nucleotide sequence that is at least 70% homologous to the nucleotide sequence shown in any one of SEQ ID No. 1-15, for example, at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%.
- the immune effector cell comprises a nucleic acid encoding a chimeric antigen receptor (CAR), and the CAR includes an antigen binding domain, a hinge region, a transmembrane domain, a costimulatory structure, and a primary signal transduction domain.
- CAR chimeric antigen receptor
- the antigen binding domain specifically binds to tumor antigens.
- the tumor antigen is selected from the following group: CD19, CD123, CD22, CD30, CD171, CA125, C-met, L1CAM, EC, DLL3, CD99, 5T4, CD138, CS-1 (also known as CD2 subclass 1 , CRACC, SLAMF7, CD319 or 19A24), C-type lectin-like molecule-1 (CLL-1 or CLECL1), CD33, epidermal growth factor receptor variant III (EGFRvIII), ganglioside G2 (GD2), nerve Ganglioside GD3, TNF receptor family member B cell maturation antigen (BCMA), Tn antigen (such as Tn Ag, GalNAc ⁇ -Ser/Thr), prostate specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan Body 1 (ROR1), Fms-like tyrosine kinase 3 (FLT3); tumor-associated glycoprotein 72
- the antigen-binding domain may include an antibody or antigen-binding fragment thereof that specifically binds to the tumor antigen.
- the antibodies or antigen-binding fragments thereof that specifically bind to GPC3 described in this application may include, but are not limited to, recombinant antibodies, monoclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, bispecific antibodies, single chain antibodies, Diabodies, triabodies, tetrabodies, Fv fragments, scFv fragments, Fab fragments, Fab' fragments, F(ab')2 fragments and camel single domain antibodies.
- the antibody may be a humanized antibody. It may be a framework (FR) region that immunospecifically binds to a relevant antigen (e.g., human CD19, BCMA, or GPC3) and contains substantially the amino acid sequence of a human antibody and a complementarity determining region that substantially has the amino acid sequence of a non-human antibody ( CDR) antibodies or variants, derivatives, analogs or fragments thereof.
- a relevant antigen e.g., human CD19, BCMA, or GPC3
- CDR non-human antibody
- the antigen-binding fragment may include Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di-scFv and/or dAb.
- the single chain antibody is scFv.
- the antigen binding domain targets solid tumors.
- the solid tumor is selected from the following group: liver cancer, gastric cancer, lung cancer, breast cancer, colon cancer, rectal cancer, renal cell cancer, liver cancer, non-small cell lung cancer, small intestine cancer, esophageal cancer, melanoma, bone cancer, Pancreatic cancer, skin cancer, head or neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin's lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, urethral cancer, penile cancer, childhood solid tumors, bladder cancer, kidney or ureter cancer, renal pelvis cancer , Central Nervous System (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal
- the antigen binding domain targets non-solid tumors.
- the non-solid tumor is selected from the following group: chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia ( T-ALL), chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), B-cell young lymphocytic leukemia, blastic plasmacytoid dendritic cell tumor, Burkitt lymphoma, diffuse large B-cell lymphoma , Follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative disease, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplastic and Myelodysplastic syndrome, non-Hodgkin’s lympho
- the transmembrane domain may comprise a transmembrane domain selected from the following proteins: CD28, CD3e, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154.
- the costimulatory domain may comprise a costimulatory domain selected from the following proteins: CD137, CD28, 4-1BB, OX-40 and ICOS.
- the intracellular signaling domain may include a signaling domain derived from CD3 ⁇ .
- the hinge region connects the antigen binding domain and the transmembrane domain, and the hinge region includes a hinge region derived from a protein selected from the group consisting of IgG1, IgG4, IgD, and CD8.
- the application also provides a composition, which includes the modified immune effector cell described in the application and a pharmaceutically acceptable carrier.
- composition includes a cell population, wherein the cell population includes the modified immune effector cells described in this application.
- the ratio of the number of modified immune effector cells to the total number of cells in the cell population is at least 0.001%, at least 0.01%, at least 0.1%, at least 1%, at least 5%, at least 10%, at least 15 %, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 53%, at least 55%, at least 58%, at least 60%, at least 63%, At least 65%, at least 68%, at least 70%, at least 73%, at least 75%, at least 78%, at least 80%, at least 83%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89 %, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%.
- the cell population may include the modified immune effector cells and corresponding immune effector cells that have not been modified.
- the modified immune effector cell may include a cell in which any one of two TRAC alleles is knocked out and any one of two HLA-A alleles is knocked out, two TRAC alleles Cells that have been knocked out and either of the two HLA-A alleles have been knocked out, cells in which either of the two TRAC alleles have been knocked out and the two HLA-A alleles have been knocked out, A cell in which two TRAC alleles have been knocked out and two HLA-A alleles have been knocked out.
- the cell population may be a cell population obtained by genetically engineering the immune effector cell population, and the genetic engineering method may include administering the immune effector cell population described in this application to the immune effector cell population.
- Antisense RNA, the siRNA, the shRNA and/or the CRISPR/Cas9 system may include the sgRNA targeting the exon portion of the HLA-A gene, the sgRNA targeting the exon portion of the TRAC gene, and the Cas9 protein.
- the cell population may include a cell population obtained by editing the immune effector cell population by the CRISPR/Cas9 system, and the editing efficiency of the editing is at least 30%, at least 35%, at least 40%, at least 45 %, at least 50%, at least 53%, at least 55%, at least 58%, at least 60%, at least 63%, at least 65%, at least 68%, at least 70%, at least 73%, at least 75%, at least 78%, At least 80%, at least 83%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95 %, at least 96%, at least 97%, at least 98%, at least 99%.
- the editing efficiency can be obtained by Sanger sequencing, TA cloning sequencing, and flow cytometry.
- the cell population may include the cell population of the immune effector cells obtained by administering the antisense RNA, the siRNA, and the shRNA described in this application, and the cell population is different from the cell population before the administration.
- mRNA expression is reduced by at least 10%, at least 20%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 53%, at least 55%, at least 58%, at least 60%, at least 63%, at least 65%, at least 68%, at least 70%, at least 73%, at least 75%, at least 78%, at least 80%, at least 83%, at least 85%, at least 86% , At least 87%, at least 88%, at least 89%, at least 90%.
- the cell population may include the cell population of the immune effector cells obtained by administering the antisense RNA, the siRNA, and the shRNA described in the present application, and the cell population is different from the cell population before the administration.
- protein expression is reduced by at least 10%, at least 20%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 53%, at least 55%, at least 58%, at least 60%, at least 63%, at least 65%, at least 68%, at least 70%, at least 73%, at least 75%, at least 78%, at least 80%, at least 83%, at least 85%, at least 86% , At least 87%, at least 88%, at least 89%, at least 90%.
- the acceptable ingredients of the composition are non-toxic to the recipient at the dosage and concentration used.
- the pharmaceutical compositions of the present invention include, but are not limited to, liquid, frozen and lyophilized compositions.
- the pharmaceutically acceptable carrier may include any and all solvents, dispersion media, isotonic agents, and absorption delaying agents that are compatible with the immune effector cells, and are generally safe, non-toxic, and neither biologically Nor is it undesirable in other respects.
- the pharmaceutically acceptable carrier may include storage solution at 2°C-8°C, cryopreservation solution, injection solution and the like.
- the carrier may include the following components: adenosine, sodium chloride, albumin, interleukin-15, angiotensin-II, short peptides and polypeptides from the serum-free culture medium of human umbilical cord mesenchymal stem cells Compound etc.
- the carrier may also include Normosol R (Abbott), Plasma-Lyte A (Baxter) injection, 5% dextrose water or Ringer's lactate solution.
- the carrier may also include glycerol or DMSO.
- the composition may comprise parenteral, transdermal, intraluminal, intraarterial, intrathecal and/or intranasal administration or direct injection into tissues.
- the composition can be administered to a patient or subject by infusion or injection.
- the administration of the pharmaceutical composition can be carried out in different ways, such as intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration.
- the pharmaceutical composition may be administered without interruption.
- the uninterrupted (or continuous) administration can be achieved by a small pump system worn by the patient to measure the therapeutic agent flowing into the patient's body, as described in WO2015/036583.
- This application also provides the application of the modified immune effector cells described in this application in the preparation of CAR-T cells.
- the application also provides the application of the modified immune effector cells described in the application in the preparation of medicines, and the medicines are used for allogeneic therapy.
- This application also provides the application of the modified immune effector cells described in this application in the preparation of medicines for the treatment of tumors.
- the tumor includes solid tumors and non-solid tumors.
- the types of the solid tumor and the non-solid tumor are as described above.
- the following examples are only to illustrate the modified immune effector cells, preparation methods and uses of the present application, and are not used to limit the scope of the present application.
- the examples do not include detailed descriptions of traditional methods, such as those used to construct vectors and plasmids, methods of inserting genes encoding proteins into such vectors and plasmids, or methods of introducing plasmids into host cells.
- Such methods are well known to those of ordinary skill in the art and are described in many publications, including Sambrook, J., Fritsch, EF and Maniais, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd edition, Cold spring Harbor Labora-tory Press.
- sgRNAs composed of 20 nucleotide sequences may appear repeatedly in the genome, use the website http://crispr.cos.uni-heidelberg.de to come. Carry out the design and evaluation of sgRNA, paste the exon sequence to the website, and design the sgRNA on the website and perform predictive evaluation. The higher the score in the evaluation, the higher the editing efficiency and the lower risk of off-target. Select the sgRNA with a higher score for the experiment.
- the sgRNA targeting the TRAC gene is shown in SEQ ID No. 1-15
- the sgRNA targeting the HLA-A02 gene is shown in SEQ ID No.
- the sgRNA targeting the HLA-A11 gene is shown in SEQ ID No. 38.
- the sgRNA targeting the HLA-A24 gene is shown in SEQ ID No. 47-54, synthesized by GenScript Biotechnology.
- Peripheral blood was collected from healthy donors and diluted 1:1 with PBS buffer.
- a new 50ml centrifuge tube first add the diluted cell separation solution (Ficoll) of 1/3 of the blood volume, and then add the blood cell diluent very slowly along the tube wall, and centrifuge at 800g at room temperature for 20 minutes (the centrifuge is set to increase speed 1, decrease speed 0).
- the liquid in the centrifuge tube is divided into PBS and serum layer, white blood cell layer, lymphocyte separation liquid, and red blood cell layer from top to bottom.
- Remove the PBS and serum layer move the white blood cell layer to a new 50ml centrifuge tube, add PBS to 40ml to wash the cells, and centrifuge at 450g for 10min. After centrifugation, the supernatant was discarded to obtain peripheral blood mononuclear cells. After the cells are resuspended, the cells are counted.
- the EasySep TM human T cell sorting kit (purchased from StemCell Technologies, catalog number: 17951) was used to extract T cells from peripheral blood mononuclear cells (PBMC). Adjust the density of PBMC to 5 ⁇ 107 cells/ml, and add PBS buffer in the range of 0.25-2ml; first add cocktail and mix and then add isolation cocktail according to 50 ⁇ l/ml.
- PBMC peripheral blood mononuclear cells
- the electroporation kit (purchased from LONZA, article number V4XXP-3024) was used to transfer the RNP complex into the activated T cells prepared in Example 2 by electroporation.
- Pre-warm the medium (X-VIVO15 medium + 10% FBS + IL2 (200U/ml) + IL7 (10ng/ml) + IL15 (5ng/ml)) in the well plate 30 minutes in advance.
- HLA-A02 Sg5 shown in SEQ ID No. 17
- SEQ ID No.18 or HLA-A11 sg21 (shown in SEQ ID No.91) or HLA-A11 Rsg2 (shown in SEQ ID No.92)
- 10 ⁇ g Cas9 protein purchased from thermo, catalog number A36499
- Count the cells take 3 ⁇ 5 ⁇ 10 4 cells, centrifuge at 2000r/min for 5min, try to remove the supernatant, then add 20 ⁇ l DE lysis buffer to each tube, add to the PCR tube after cell lysis, and transfer to the PCR machine after transient centrifugation.
- Machine conditions 65°C for 30min, 4°C for 30s, 95°C for 2min, 16°C infinite.
- Use the primer pair TRAC-For/TRAC-Rev, or HLA-A For/HLA-A Rev and use the cleavage product as a template for PCR.
- the PCR primer sequence is shown in SEQ ID NO.66-81, and the PCR product is sent to Jin Weizhi Perform Sanger sequencing. After getting the sanger sequencing results, use the EditR editor in the website: https://moriaritylab.shinyapps.io/editr_v10/ to predict where the editing will occur and the editing efficiency.
- the three detection results of TRAC single gene knockout are shown in Figures 1 to 3, and the calculation results of knockout efficiency are shown in Table 1.
- the three detection methods are basically the same, and subsequent experiments only use the Sanger sequencing method to detect editing efficiency.
- the electroporation kit (purchased from LONZA, article number: V4XXP-3024) was used to transfer the RNP complex into the activated T cells prepared in Example 2 by electroporation. Pre-warm the medium (X-VIVO15 medium + 10% FBS + IL2 (200U/ml) + IL7 (10ng/ml) + IL15 (5ng/ml)) in the well plate 30 minutes in advance.
- RNP complex 20 ⁇ g TRAC sgRNA (TRAC Sg9), 20 ⁇ g HLA-A sgRNA (HLA-A02 Sg2 or HLA-A02 Sg5 or HLA-A11 sg21 or target HLA-A*24:02:01, HLA- A*30:01:01:01, HLA-A*33:01:01:01, HLA-A*03:01:01:01, HLA-A*01:01:01:01 or HLA-A* 26:01:01:01:01 sgRNA) was added to the PCR tube (no RNA), and then 10 ⁇ g Cas9 protein (purchased from thermo, catalog number A36499) was added to each of them, mixed gently, and incubated at room temperature for 12min.
- Example 2 Count the activated T cells cultured in Example 2, centrifuge at 300g for 8min to discard the supernatant, add PBS to resuspend the cells, aspirate 1E7 cells and centrifuge again at 300g for 8min, discard the supernatant and resuspend the cells with 100 ⁇ l of the prepared electroporation buffer .
- Add the pre-warmed culture medium to the electrospindle then transfer the cells into the pre-heated culture medium in the well plate with a matching pipette, and then place it in a 37°C, 5% CO 2 incubator for culture.
- the double gene knockout efficiency can be detected by sequencing, and TRAC-negative and HLA-A-negative T cells whose double-gene knockout efficiency is not less than 80% can be obtained.
- the result is shown in Figure 8-9.
- Figure 8A shows the results of using HLA-A02 Sg5 to knock out HLA-A02, the upper row shows the results of the control group (that is, without using HLA-A02 Sg5 for knockout); the next row shows the simultaneous knockout of HLA -The results of A02 and TRAC;
- Figure 8B shows the results of knocking out TRAC with TRAC Sg9, and the upper line shows the results of the control group (that is, the results of TRAC Sg9 are not used for knockout); the next line shows the simultaneous knockout Results of HLA-A02 and TRAC.
- Example 2 (1) Using the activated T cells prepared in Example 2, they were divided into two groups, one group was used as a control, and the other group was prepared according to the method of Example 5 with double knockout T cells of the TRAC gene and HLA-A gene. Sanger sequencing was performed in step (1) of Example 4. According to the sequencing results, cells with TRAC and HLA-A double gene knockout were obtained. The prepared double gene knockout T cells are incubated with the corresponding TRAC and HLA-A antibodies, and the double gene knockout cell line can be obtained by flow sorting or magnetic bead sorting.
- RNA extraction kit purchased from QIAGEN, article number: 74004
- reverse transcription kit purchased from Applied Biosystems, article number: 4368814
- cDNA was used as a template for quantitative PCR detection.
- Figure 10-11 The result is shown in Figure 10-11.
- Figure 10 shows the mRNA level measurement of gene expression
- Figures 10A-10D show the mRNA levels of TRAC, HLA-A, B2M and CIITA respectively
- WT refers to the situation without any knock-out treatment
- double-knock group Refers to the result of T cell knockout of TRAC gene and HLA-A gene
- Figure 11 shows the protein level determination of gene expression, in which Figures 11A-11B show the protein expression levels of B2M and CIITA respectively
- NEG refers to the negative control
- WT refers to the condition without any knock-out treatment
- TRAC+HLA-A Double knockout refers to the result of double knockout of TRAC gene and HLA-A gene.
- Example 7 Preparation of TRAC gene, HLA-A/B2M gene and CIITA gene knockout T cells and verify the expression changes of the corresponding three genes
- TRAC, HLA-A and CIITA genes in T cells with TRAC, HLA-A and CIITA knockout was down-regulated; compared with control cells, TRAC, B2M and CIITA were knocked out
- the protein expression of TRAC, HLA-A and CIITA genes in T cells was down-regulated.
- FIGS 12A-12D show the knockout of TRAC, HLA-A and B2M protein levels in sequence.
- WT refers to the situation without any knockout treatment
- TRAC+HLA-A double knockout refers to the results of T cells with double knockout of TRAC gene and HLA-A gene
- TRAC+HLA-A+CIITA triple knockout refers to TRAC
- TRAC+B2M+CIITA triple-knockout refers to the results of B2M, CIITA, and TRAC three-gene knock-out T cells
- TRAC+HLA-A knockdown refers to Example 9
- Figure 12D shows the knockout of CIITA protein levels.
- A is adenylate
- T is thymidylate
- R is adenylate or guanylate (purine)
- Y is thymidylate or cytidine Acids (pyrimidines)
- N is adenylate, thymidylate, guanylate or cytidine acid; compare the homology of selected sequences to avoid significant homology between antisense RNA and other genes or sequences , Resulting in off-target effects.
- the homology analysis uses NCBI B
- the designed antisense RNA sequence includes HLA-A-homo-551 (which includes the nucleotide sequence shown in SEQ ID NO.93); HLA-A-homo-NEG (which includes the nucleotide sequence shown in SEQ ID NO.94) Nucleotide sequence); TRAC-homo-375 (it includes the nucleotide sequence shown in SEQ ID NO. 95); TRAC-homo-NEG (it includes the nucleotide sequence shown in SEQ ID NO. 96).
- the antisense RNA designed in Example 8 was used for double gene knockdown.
- the company prepares a lentivirus (Zima) with TRAC gene and HLA-A gene antisense RNA sequence.
- CD3 + T cells were prepared according to the method of Example 2 (D0 day), and activated with CD3/CD28 antibody magnetic beads, which will carry the antisense RNA sequences of the TRAC gene and the HLA-A gene (SEQ ID NO. 95 and SEQ ID NO.
- the activated T cells were transfected with the lentivirus of 93) (D1 day), the lentiviral vector was washed off on D2, and the culture was continued to D5. Collect T cells cultured to D5 days, and detect gene knockdown efficiency by quantitative PCR or Western Blot.
- T cells with TRAC gene and HLA-A gene knockdown can be obtained through flow sorting or magnetic bead sorting.
- the results showed that the mRNA and protein expression levels of TRAC and HLA-A in the TRAC and HLA-A gene knockdown group were down-regulated.
- Figures 13A-13B show the knockout of TRAC and HLA-A mRNA levels in sequence.
- WT refers to the situation without any knock-out treatment
- TRAC+HLA-A double knock refers to the result of double knockout of TRAC gene and HLA-A gene.
- the knockout levels of TRAC and HLA-A protein levels can be seen in the results in FIG. 12.
- Example 10 The difference between different T cell activities
- TRAC+HLA-A double knockout refers to the results of T cells with double knockout of TRAC gene and HLA-A gene
- TRAC+HLA-A+CIITA triple knockout refers to TRAC
- TRAC+B2M+CIITA triple-knockout refers to the results of B2M, CIITA, and TRAC three-gene knock-out T cells
- TRAC+HLA-A knockdown refers to Example 9 The prepared TRAC gene and HLA-A gene knockdown T cell result.
- T cells without gene knockout, double gene knockout, three gene knockout, and double gene knockdown in Examples 2, 5, 7 and 9 were labeled with CFSE (invitrogen, C34554), and the cell count was 1 respectively.
- CFSE invitrogen, C34554
- *10 6 cells were co-cultured with NK cells (NK92MI) at a ratio of 1:1. After 24 hours, the co-cultured groups of cells were collected, and the ratio of CFSE-positive cells in the mixed cells was detected by flow cytometry.
- NK+T refers to the situation where NK cells are co-cultured with T cells that have not undergone any knock-out treatment
- NK+TRAC+HLA-A knockdown refers to NK cells with the TRAC gene and HLA-A gene prepared in Example 9
- the results of knockdown T cells are co-cultured
- NK+TRAC+HLA-A double knocking refers to the co-cultivation of NK cells and T cells with double knockout of TRAC gene and HLA-A gene
- NK+TRAC+HLA -A+CIITA triple knocking refers to the situation where NK cells are co-cultured with TRAC, HLA-A and CIITA knockout T cells
- NK+TRAC+B2M+CIITA triple knocking refers to the situation where NK cells are combined with B2M, CIITA and
- Example 12 The difference between different T cell allogeneic immune rejection reactions
- Peripheral blood from Donor 1 was used to prepare T cells without gene knockout, double gene knockout, three gene knockout, and double gene knockdown in Examples 2, 5, 7, and 9.
- CD3 + T cells were prepared from peripheral blood from donor 2. Each group of cells prepared from the peripheral blood of Donor 1 was mixed with the peripheral blood of Donor 2 in equal proportions with the CD3 + T cells prepared in Example 2. After 24 hours, the expression level of IFN- ⁇ in the cell mixed system was measured. The results showed that the expression level of IFN- ⁇ in the double-knockout T cell group was lower than that in the triple-knockout T cell group.
- TRAC+HLA-A double knock refers to the results of T cells with double knockout of TRAC gene and HLA-A gene
- TRAC+HLA-A+CIITA Triple knockout refers to the results of TRAC, HLA-A and CIITA three gene knockout T cells
- TRAC+B2M+CIITA triple knockout refers to the results of B2M, CIITA and TRAC three gene knockout T cells
- TRAC+HLA-A knockout Low refers to the result of knockdown of TRAC gene and HLA-A gene prepared in Example 9.
- Example 13 Preparation of CAR-T cells with double knockout of TRAC gene and HLA-A gene, CAR-T cells with triple knockout of TRAC gene, HLA-A gene and CIITA gene, and TRAC gene, B2M gene and CIITA gene Knockout CAR-T cells
- Example 2 (1) Obtain CD3 + T cells (day D0) according to the method of Example 2, and activate them with CD3/CD28 antibody magnetic beads. After activation, perform lentiviral vectors (including CD19-CAR, CD20-CAR or BCMA-CAR) on day D1. Transfection with other lentivirus), wash off the lentiviral vector on D2, sort CAR-positive T cells on D3 and continue to culture until D5.
- lentiviral vectors including CD19-CAR, CD20-CAR or BCMA-CAR
- TRAC gene and HLA-A gene double gene knockout cells Take CAR-T cells on D5 days as initial cells, prepare TRAC gene and HLA-A gene double gene knockout cells according to the method in Example 5 and Example 7, respectively, TRAC gene, HLA-A gene CAR-T cells with CIITA gene, TRAC gene, B2M gene and CIITA gene knockout.
- the above-mentioned double gene knockout and triple gene knockout CAR-T cells can be obtained by flow cytometry detection, and the yield of double gene knockout CAR-T cells is higher than that of triple gene knockout CAR-T cells.
- Figures 17A-17D show the knockout of TRAC, HLA-A and B2M protein levels in sequence.
- Figure 17D shows the knockout of CIITA protein levels.
- WT refers to the condition without any knockout treatment
- TRAC+HLA-A double knockout refers to the results of CAR-T cells with double knockout of TRAC gene and HLA-A gene
- TRAC+HLA-A+CIITA triple knockout The results of CAR-T cells with TRAC, HLA-A and CIITA knockouts
- TRAC+B2M+CIITA knockout refers to the results of CAR-T cells with B2M, CIITA and TRAC knockouts.
- the transfection efficiency of CD19CAR is shown in Figures 18A-18B.
- CAR30%+ represents the transfection efficiency of CD19 CAR.
- Figure 19 shows the fold expansion of different cells. Among them, CAR-T cells with double gene knockout of TRAC gene and HLA-A gene had the highest amplification factor.
- Figure 20 shows the killing effect on CD19 target cells Raji-Luciferase, among which CAR-T cells with double knockout of TRAC gene and HLA-A gene have the most significant killing effect.
- each E/T ratio is the result corresponding to the legend A-D from left to right.
- mice were injected intravenously with tumor cells. After the tumor was successfully established, the mice were infused with CAR-T cells with double gene knockout of TRAC gene and HLA-A gene, CAR-T cells with triple gene knockout or without gene knockout. T cells to monitor the tumor volume in mice.
- Tumor growth rate was significantly slowed in mice with double-gene knockout CAR-T cells.
- Figure 21-22 shows the way of administration to mice, i.v. means intravenous injection, CAR-T cells represent double-knockout CAR-T cells expressing CD19 CAR, and triple-knockout CAR-T cells.
- Figure 20 shows the volume of tumors in mice after the administration of CAR-T cells. Among them, Figure 20 shows from left to right the three genes of CD19 CAR-T cells, TRAC, HLA-A, and CIITA that have been treated with physiological saline, unmodified T cells, TRAC gene and HLA-A gene double gene knockout, respectively.
- mice The volume of tumors in mice after knockout of CD19 CAR-T cells, B2M, CIITA, and TRAC CD19 CAR-T cells. It was found that the mice that were injected with CAR-T cells with double knockout of TRAC gene and HLA-A gene, the tumor growth rate was significantly slowed down.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
Abstract
Description
Claims (49)
- 经修饰的免疫效应细胞,其中与未经所述修饰的相应细胞中相应基因的表达和/或活性相比,TRAC基因和HLA-A基因的表达和/或活性被下调,B2M基因的表达和/或活性未被下调,且CIITA基因的表达和/或活性未被下调。
- 根据权利要求1所述的免疫效应细胞,其中所述修饰使得两种基因的表达和/或活性被下调,其中所述两种基因由TRAC基因和HLA-A基因组成。
- 根据权利要求1-2中任一项所述的免疫效应细胞,其中与相应的野生型细胞相比,TRAC基因和HLA-A基因的表达和/或活性被下调,B2M基因的表达和/或活性未被下调,且CIITA基因的表达和/或活性未被下调。
- 根据权利要求1-3中任一项所述的免疫效应细胞,其中与相应的野生型细胞相比,两种基因的表达和/或活性被下调,其中所述两种基因由TRAC基因和HLA-A基因组成。
- 根据权利要求1-4中任一项所述的免疫效应细胞,其中所述免疫效应细胞包括T细胞。
- 根据权利要求1-5中任一项所述的免疫效应细胞,其中所述基因的表达水平和/或活性被下调包括使编码所述基因的核酸分子的表达和/或活性下调;和/或使所述基因编码的蛋白质产物的表达和/或活性被下调。
- 根据权利要求1-6中任一项所述的免疫效应细胞,其中所述修饰包括:基因突变和/或基因沉默。
- 根据权利要求1-7中任一项所述的免疫效应细胞,其中所述修饰包括向所述免疫效应细胞施用一种或多种选自下组的物质:反义RNA、siRNA、shRNA和CRISPR/Cas9系统。
- 根据权利要求1-8中任一项所述的免疫效应细胞,其中所述修饰包括向所述免疫效应细胞施用CRISPR/Cas9系统。
- 根据权利要求1-9中任一项所述的免疫效应细胞,其中所述修饰包括向所述免疫效应细胞施用靶向所述HLA-A基因外显子部分的sgRNA。
- 根据权利要求1-10中任一项所述的免疫效应细胞,其中所述修饰还包括向所述免疫效应细胞施用靶向所述TRAC基因外显子部分的sgRNA。
- 根据权利要求10所述的免疫效应细胞,其中所述靶向所述HLA-A基因外显子部分的sgRNA包含SEQ ID No.16-54、91-92中任一项所示的核苷酸序列。
- 根据权利要求12所述的免疫效应细胞,其中所述靶向所述TRAC基因外显子部分的sgRNA包含SEQ ID No.1-15中任一项所示的核苷酸序列。
- 根据权利要求8-13中任一项所述的免疫效应细胞,其中所述反义RNA包含SEQ ID No.93-96中任一项所示的核苷酸序列。
- 根据权利要求1-14中任一项所述的免疫效应细胞,其中所述修饰还包括向所述细胞施用 Cas酶。
- 根据权利要求15所述的免疫效应细胞,其中Cas酶包括Cas9蛋白。
- 根据权利要求1-16中任一项所述的免疫效应细胞,其中所述免疫效应细胞包含编码嵌合抗原受体(CAR)的核酸,所述CAR包括抗原结合结构域、铰链区、跨膜结构域、共刺激结构和初级信号传导结构域。
- 根据权利要求17所述的免疫效应细胞,其中所述抗原结合结构域特异性地结合肿瘤抗原。
- 根据权利要求17所述的免疫效应细胞,其中所述肿瘤抗原选自以下组:CD19、CD20和BCMA。
- 根据权利要求17-19中任一项所述的免疫效应细胞,其中所述抗原结合结构域选自以下组:单克隆抗体、多克隆抗体、人抗体、人源化抗体、单域抗体和其抗原结合片段。
- 根据权利要求17-20中任一项所述的免疫效应细胞,其中所述抗原结合结构域靶向实体瘤。
- 根据权利要求21所述的免疫效应细胞,其中所述实体瘤选自以下组:肝癌、胃癌、肺癌、乳腺癌和非小细胞肺癌。
- 根据权利要求17-20中任一项所述的免疫效应细胞,其中所述抗原结合结构域靶向非实体瘤。
- 根据权利要求23所述的免疫效应细胞,其中所述非实体瘤选自以下组:B淋巴细胞瘤、霍奇金淋巴瘤、慢性髓性白血病和急性髓样白血病。
- 根据权利要求17-24中任一项所述的免疫效应细胞,其中所述跨膜结构域包含源自选自下述蛋白的跨膜结构域:CD28、CD3e、CD27、CD3ε和CD45。
- 根据权利要求17-25中任一项所述的免疫效应细胞,其中所述共刺激结构域包含选自下述蛋白的共刺激结构域:CD137、CD28、CD27、OX40和CD30。
- 根据权利要求17-26中任一项所述的免疫效应细胞,其中所述铰链区连接所述抗原结合结构域和所述跨膜结构域,所述铰链区包含源自选自下述蛋白的铰链区:人免疫球蛋白铰链区、GS接头、KIR2DS2铰链区和CD8a铰链区。
- 制备权利要求1-27中任一项所述的经修饰的免疫效应细胞的方法,其包括以下的步骤:与未经所述修饰的相应细胞中相应基因的表达和/或活性相比,下调所述免疫效应细胞中TRAC基因和HLA-A基因的表达和/或活性;不下调B2M基因的表达和/或活性,且不下调CIITA基因的表达和/或活性。
- 根据权利要求28所述的方法,其中所述修饰使得两种基因的表达和/或活性被下调,其 中所述两种基因由TRAC基因和HLA-A基因组成。
- 根据权利要求28-29中任一项所述的方法,与相应的野生型细胞相比,TRAC基因和HLA-A基因的表达和/或活性被下调,B2M基因的表达和/或活性未被下调,且CIITA基因的表达和/或活性未被下调。
- 根据权利要求28-30中任一项所述的方法,与相应的野生型细胞相比,两种基因的表达和/或活性被下调,其中所述两种基因由TRAC基因和HLA-A基因组成。
- 根据权利要求28-31中任一项所述的方法,其中所述下调基因的表达水平和/或活性包括使编码所述基因的核酸分子的表达和/或活性下调;和/或使所述基因编码的蛋白质产物的表达和/或活性被下调。
- 根据权利要求28-32中任一项所述的方法,其中所述修饰包括:基因突变和/或基因沉默。
- 根据权利要求28-33中任一项所述的方法,其中所述修饰包括向所述免疫效应细胞施用一种或多种选自下组的物质:反义RNA、siRNA、shRNA和CRISPR/Cas9系统。
- 根据权利要求28-34中任一项所述的方法,其中所述修饰包括向所述免疫效应细胞施用CRISPR/Cas9系统。
- 根据权利要求28-35中任一项所述的方法,其中所述修饰包括向所述免疫效应细胞施用靶向所述HLA-A基因外显子部分的sgRNA。
- 根据权利要求28-36中任一项所述的方法,其中所述修饰包括向所述免疫效应细胞施用靶向所述TRAC基因外显子部分的sgRNA。
- 根据权利要求36所述的方法,其中所述靶向所述HLA-A基因外显子部分的sgRNA包含SEQ ID No.16-54、91-92中任一项所示的核苷酸序列。
- 根据权利要求37所述的方法,其中所述靶向所述TRAC基因外显子部分的sgRNA包含SEQ ID No.1-15中任一项所示的核苷酸序列。
- 根据权利要求34-39中任一项所述的方法,其中所述反义RNA包含SEQ ID No.93-96中任一项所示的核苷酸序列。
- 根据权利要求34-40任一项所述的方法,其中所述修饰还包括向所述细胞施用Cas酶。
- 根据权利要求41所述的方法,其中Cas酶包括Cas9蛋白。
- 组合物,其包括权利要求1-27中任一项所述的免疫效应细胞和药学上可接受的载体。
- 根据权利要求43所述的组合物,其包含细胞群,其中所述细胞群包含权利要求1-27中任一项所述的免疫效应细胞。
- 权利要求1-27中任一项所述的免疫效应细胞在制备CAR-T细胞中的应用。
- 权利要求1-27中任一项所述的免疫效应细胞在制备药物中的应用,所述药物用于异体治疗。
- 权利要求1-27中任一项所述的免疫效应细胞在制备药物中的应用,所述药物用于治疗肿瘤。
- 根据权利要求47所述的应用,其中所述肿瘤包括实体瘤和非实体瘤。
- 根据权利要求47-48中任一项所述的应用,其中所述肿瘤选自以下组:肝癌、胃癌、肺癌、乳腺癌、非小细胞肺癌、B淋巴细胞瘤、霍奇金淋巴瘤、慢性髓性白血病和急性髓样白血病。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022540754A JP2023508740A (ja) | 2020-01-02 | 2020-12-29 | 修飾された免疫エフェクター細胞及びその調製方法 |
KR1020227026014A KR20220124197A (ko) | 2020-01-02 | 2020-12-29 | 변형된 면역 효과기 세포 및 이의 제조 방법 |
CA3163304A CA3163304A1 (en) | 2020-01-02 | 2020-12-29 | Modified immune effector cell and preparation method therefor |
EP20911252.3A EP4086342A4 (en) | 2020-01-02 | 2020-12-29 | MODIFIED IMMUNE EFFECTOR CELL AND METHOD FOR THE PRODUCTION THEREOF |
CN202080090688.0A CN115003802B (zh) | 2020-01-02 | 2020-12-29 | 一种经修饰的免疫效应细胞及其制备方法 |
AU2020418199A AU2020418199B2 (en) | 2020-01-02 | 2020-12-29 | Modified immune effector cell and preparation method therefor |
US17/563,804 US20220193135A1 (en) | 2020-01-02 | 2021-12-28 | Modified immune effector cell and preparation method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010002929.3 | 2020-01-02 | ||
CN202010002929 | 2020-01-02 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/563,804 Continuation US20220193135A1 (en) | 2020-01-02 | 2021-12-28 | Modified immune effector cell and preparation method therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021136263A1 true WO2021136263A1 (zh) | 2021-07-08 |
Family
ID=76559305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/140799 WO2021136263A1 (zh) | 2020-01-02 | 2020-12-29 | 一种经修饰的免疫效应细胞及其制备方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220193135A1 (zh) |
EP (1) | EP4086342A4 (zh) |
JP (1) | JP2023508740A (zh) |
KR (1) | KR20220124197A (zh) |
CN (2) | CN115003802B (zh) |
AU (1) | AU2020418199B2 (zh) |
CA (1) | CA3163304A1 (zh) |
WO (1) | WO2021136263A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023164688A1 (en) * | 2022-02-28 | 2023-08-31 | Kite Pharma, Inc. | Allogeneic therapeutic cells |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112852748B (zh) * | 2020-04-16 | 2023-11-21 | 成都仕康美生物科技有限公司 | 靶向HLA-A的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途 |
JP2024527557A (ja) * | 2021-07-01 | 2024-07-25 | 寧波茂行生物医薬科技有限公司 | B7h3を標的とする抗原結合ポリペプチド及びその応用 |
CN117940138A (zh) * | 2021-07-01 | 2024-04-26 | 宁波茂行生物医药科技有限公司 | 靶向egfr的通用型car-t细胞及其制备方法 |
US20240139321A1 (en) * | 2021-07-01 | 2024-05-02 | Ningbo T-Maximum Biopharmaceuticals Co., Ltd. | Universal car-t cell targeting gd2, preparation method therefor, and application thereof |
WO2023151620A1 (zh) * | 2022-02-09 | 2023-08-17 | 恺兴生命科技(上海)有限公司 | 用于细胞免疫学的组合物和方法 |
WO2024094165A1 (zh) * | 2022-11-04 | 2024-05-10 | 茂行制药(苏州)有限公司 | 靶向b7h3的通用型car-t细胞及其制备方法和应用 |
WO2024159713A1 (zh) * | 2023-01-30 | 2024-08-08 | 南京北恒生物科技有限公司 | 用于CRISPR-Cas基因编辑系统的方法及组合物 |
CN118325904A (zh) * | 2024-06-17 | 2024-07-12 | 天海元祺生物科技(天津)有限公司 | 高度靶向人类HLA-A基因的sgRNA、其组合物及应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
WO2015036583A2 (en) | 2013-09-13 | 2015-03-19 | Amgen Inc. | Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia |
CN107206024A (zh) * | 2014-10-31 | 2017-09-26 | 宾夕法尼亚大学董事会 | 改变cart细胞中的基因表达及其用途 |
CN107630006A (zh) * | 2017-09-30 | 2018-01-26 | 山东兴瑞生物科技有限公司 | 一种制备tcr与hla双基因敲除的t细胞的方法 |
CN107723275A (zh) * | 2017-10-20 | 2018-02-23 | 重庆精准生物技术有限公司 | 通用型car‑t细胞及其制备方法和应用 |
CN108699557A (zh) * | 2015-12-04 | 2018-10-23 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
CN109456943A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技(上海)有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
CN109750035A (zh) * | 2017-11-02 | 2019-05-14 | 上海邦耀生物科技有限公司 | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA |
WO2019097305A2 (en) * | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技(上海)有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
-
2020
- 2020-12-29 JP JP2022540754A patent/JP2023508740A/ja active Pending
- 2020-12-29 AU AU2020418199A patent/AU2020418199B2/en active Active
- 2020-12-29 WO PCT/CN2020/140799 patent/WO2021136263A1/zh active Application Filing
- 2020-12-29 EP EP20911252.3A patent/EP4086342A4/en active Pending
- 2020-12-29 CN CN202080090688.0A patent/CN115003802B/zh active Active
- 2020-12-29 CN CN202011605256.7A patent/CN113061580B/zh active Active
- 2020-12-29 KR KR1020227026014A patent/KR20220124197A/ko unknown
- 2020-12-29 CA CA3163304A patent/CA3163304A1/en active Pending
-
2021
- 2021-12-28 US US17/563,804 patent/US20220193135A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
WO2015036583A2 (en) | 2013-09-13 | 2015-03-19 | Amgen Inc. | Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia |
CN107206024A (zh) * | 2014-10-31 | 2017-09-26 | 宾夕法尼亚大学董事会 | 改变cart细胞中的基因表达及其用途 |
CN108699557A (zh) * | 2015-12-04 | 2018-10-23 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
WO2019097305A2 (en) * | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
CN109456943A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技(上海)有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
CN107630006A (zh) * | 2017-09-30 | 2018-01-26 | 山东兴瑞生物科技有限公司 | 一种制备tcr与hla双基因敲除的t细胞的方法 |
CN107723275A (zh) * | 2017-10-20 | 2018-02-23 | 重庆精准生物技术有限公司 | 通用型car‑t细胞及其制备方法和应用 |
CN109750035A (zh) * | 2017-11-02 | 2019-05-14 | 上海邦耀生物科技有限公司 | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA |
Non-Patent Citations (21)
Title |
---|
BRUEGGEMANN, M. ET AL., YEARIMMUNOL, vol. 7, 1993, pages 33 - 40 |
DAO ET AL., SCI TRANSL MED, vol. 5, no. 176, 2013, pages 176 - 33 |
GETTS, D. ET AL.: "Synthetic T Cell Receptor-based Lymphocytes for Cancer Therapy", ADVANCED DRUG DELIVERY REVIEWS, vol. 141, 15 February 2019 (2019-02-15), pages 47 - 54, XP085750644, DOI: 10.1016/j.addr.2019.04.002 * |
HOOGENBOOM, H.R.WINTER, G., J.MOL.BIOL., vol. 227, 1992, pages 381 - 388 |
JAKOBOVITS, A. ET AL., NATURE, vol. 362, 1993, pages 255 - 258 |
JAKOBOVITS, A. ET AL., PROC.NATL.ACAD.SCI.USA, vol. 90, 1993, pages 2551 - 2555 |
JINEK ET AL., SCIENCE, vol. 337, no. 6096, 2012, pages 816 - 821 |
MAKAROVA ET AL., NAT REV MICROBIOL, vol. 13, no. 11, 2015, pages 722 - 36 |
MALI ET AL., SCIENCE, vol. 399, no. 6121, 2013, pages 823 - 826 |
MARKS, J.D. ET AL., J.MOL.BIOL., vol. 222, 1991, pages 581 - 597 |
SAMBROOK, J.FRITSCH, E. F.MANIAIS, T.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORA-TORY PRESS |
SASTRY ET AL., J VIROL., vol. 85, no. 5, 2011, pages 1935 - 1942 |
See also references of EP4086342A4 |
SERGEEVA ET AL., BLOOD, vol. 117, no. 16, 2011, pages 4262 - 4272 |
SHMAKOV ET AL., MOLECULAR CELL, vol. 60, 2015, pages 385 - 397 |
TASSEV ET AL., CANCER GENE THER, vol. 19, no. 2, 2012, pages 84 - 100 |
VAN DIJK, M.A.VAN DE WINKEL, J.G., CURR.OPIN.CHEM.BIOL., vol. 5, 2001, pages 368 - 374 |
VERMA ET AL., J IMMUNOL, vol. 184, no. 4, 2010, pages 2156 - 2165 |
WANG ET AL., CELL, vol. 153, no. 4, 2013, pages 910 - 918 |
WILLEMSEN ET AL., GENE THER, vol. 8, no. 21, 2001, pages 1601 - 1608 |
ZETSCHE ET AL., CELL, vol. 163, 2015, pages 1 - 13 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023164688A1 (en) * | 2022-02-28 | 2023-08-31 | Kite Pharma, Inc. | Allogeneic therapeutic cells |
Also Published As
Publication number | Publication date |
---|---|
EP4086342A1 (en) | 2022-11-09 |
EP4086342A4 (en) | 2024-05-15 |
JP2023508740A (ja) | 2023-03-03 |
US20220193135A1 (en) | 2022-06-23 |
CN115003802A (zh) | 2022-09-02 |
CN113061580A (zh) | 2021-07-02 |
KR20220124197A (ko) | 2022-09-13 |
AU2020418199B2 (en) | 2024-06-13 |
CN115003802B (zh) | 2024-09-03 |
CN113061580B (zh) | 2022-09-06 |
CA3163304A1 (en) | 2021-07-08 |
AU2020418199A1 (en) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021136263A1 (zh) | 一种经修饰的免疫效应细胞及其制备方法 | |
US20230295296A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
US20230355673A1 (en) | Chimeric antigen receptors targeting tim-1 | |
US20200370012A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
US20210171909A1 (en) | Methods of making chimeric antigen receptor?expressing cells | |
US20230074800A1 (en) | Car-t cell therapies with enhanced efficacy | |
WO2020210678A1 (en) | Methods of making chimeric antigen receptor-expressing cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20911252 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3163304 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022540754 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020418199 Country of ref document: AU Date of ref document: 20201229 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227026014 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202217043947 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020911252 Country of ref document: EP Effective date: 20220802 |